The TOPACIO trial (Study ID#: NCT02657889) will evaluate niraparib in combination with pembrolizumab in patients with triple-negative breast cancer or OC-Pt. The primary

**5. Combination strategies with immunotherapy**

tive in patients with persistent OC including those with OC-Pt.

research and are highlighted below.

**5.1. Checkpoint inhibitor + PARP inhibitor**

in OC-Pt.

160 Cancer Management and Therapy

treating OC.

The OCTOVA study (Study ID#: NCT03117933), is currently recruiting participants for a randomized phase II trial investigating the efficacy of chemotherapy plus olaparib and cediranib combination therapy in patients with BRCA-mutated OC-Pt. Patients will be randomized to one of three treatment groups: olaparib only, olaparib and cediranib, and the control group paclitaxel. The aim is to compare efficacy and tolerability of the three treatments.

#### **5.3. Checkpoint inhibitor + anti-angiogenic agent**

A phase II study (Study ID#: NCT02659384) to evaluate the combination of atezolizumab plus bevacizumab and acetylsalicylic acid in recurrent OC-Pt is currently recruiting. The primary aim is to determine PFS at 6 months by RECIST.

#### **5.4. Checkpoint inhibitors + cancer vaccine**

The administration of ipilimumab in 11 patients with metastatic ovarian carcinoma after vaccination with irradiated autologous tumor cells engineered to secrete GM-CSF (GVAX), showed promising results [95]. Three patients achieved stable disease as measured by CA-125 levels, and one patient achieved an objective response by radiographic criteria and maintained disease control over 4 years with regular infusions of anti-CTLA-4 antibody.

## **6. Challenges and future perspectives**

There are still many hurdles to overcome in the treatment of OC-Pt but some progress has been made in recent years, especially with the development of new immunotherapeutic agents. The good news is that OC cancer is a targetable tumor and although the OC-Pt subgroup of patients have biologically distinct tumors, both targeted therapies and immunotherapy offer an opportunity to uniquely address these differences. As new agents are developed in these categories, the main challenge with existing and future clinical trials will be the risk of adverse events and toxicities, especially with combination immunotherapeutic regimens, where there is an elevated risk for adverse immune events. A second challenge is the optimization of the dose and schedule of immunotherapeutic combinations in order to maximize the overall risk-benefit profile of a given combination. This requires multiple clinical trials with dose escalation studies that can be expensive. This approach is necessary however, especially in the setting of platinum-resistant OC cancer where much research is still needed.

## **Author details**

Arkene Levy\* and Patricia C. Rose \*Address all correspondence to<EMAIL_ADDRESS>Nova Southeastern University, Florida, USA

## **References**

[1] Siegel RL, Miller KD, Jemal A. Cancer statistics, 2017. CA: A Cancer Journal for Clinicians. 2017;**67**(1):7-30. DOI: 10.3322/caac.21387

[12] Komatsu M, Sumizawa T, Mutoh M, Chen ZS, Terada K, Furukawa T, Yang XL, Gao H, Miura N, Sugiyama T, Akiyama S. Copper-transporting P-type adenosine triphosphatase (ATP7B) is associated with cisplatin resistance. Cancer Research. 2000;**60**(5):1312-1316

Targeted Therapies in Platinum-Resistant Ovarian Cancer: Advances in Immunotherapy…

http://dx.doi.org/10.5772/intechopen.72017

163

[13] Song I, Savaraj N, Siddik Z, Liu P, Wei Y, Wu C, Kuo M. Role of human copper transporter Ctr1 in the transport of platinum-based antitumor agents in cisplatin-sensitive and cisplatin-resistant cells. Molecular Cancer Therapeutics. 2004;**3**(12):1543-1549

[14] Hudson LG, Zeineldin R, Silberberg M, Stack MS. Activated epidermal growth factor receptor in ovarian cancer. Cancer Treatment and Research. 2009;**149**:203-226. DOI:

[15] Reboe M, Levy A, Dhandyuthapani S, Rathinavelu A. Y15 enhances the cytotoxic profile of cisplatin, paclitaxel and vitamin E in platinum resistant ovarian cancer cells. The

[16] Bean LM, Sulzmaier FJ, Tancioni I, Uryu S, Jean C, Chen XL, Kleinschmidt EG, Anderson KM, Cordasco EA, Axelrod J, et al. FAK inhibition re-sensitizes platinum-resistant serous ovarian cancer. American Journal of Cancer Research. 2016;**76**(14):3812. DOI: 10.1158/

[17] Vaughan S, Coward JI, Bast RC Jr, et al. Rethinking ovarian cancer: Recommendations for improving outcomes. Nature Reviews. Cancer. 2011;**11**(10):719-725. DOI: 10.1038/

[18] Farmer H, McCabe N, Lord CJ, et al. Targeting the DNA repair defect in BRCA mutant cells as a therapeutic strategy. Nature. 2005;**434**(7035):917-921. DOI: 10.1038/

[19] Bryant HE, Schultz N, Thomas HD, et al. Specific killing of BRCA2-deficient tumours with inhibitors of poly(ADP-ribose) polymerase. Nature. 2005;**434**(7035):913-917. DOI:

[20] Krishnakumar R, Kraus WL. The PARP side of the nucleus: Molecular actions, physiological outcomes, and clinical targets. Molecular Cell. 2010;**39**:8-24. DOI: 10.1016/j.

[21] Virág L, Szabó C. The therapeutic potential of poly(ADP-ribose) polymerase inhibitors.

[22] Houtgraaf JH, Versmissen J, van der Giessen WJ. A concise review of DNA damage checkpoints and repair in mammalian cells. Cardiovascular Revascularization Medicine.

[23] Berghammer H, Ebner M, Marksteiner R, Auer B. pADPRT-2: A novel mammalian polymerizing (ADP-ribosyl) transferase gene related to truncated pADPRT homologues

in plants and *Caenorhabditis elegans*. FEBS Letters. 1999;**449**:259-263

10.1007/978-0-387-98094-2\_10

Faseb Journal. 2015;**29**:785.1

1538-7445.AM2016-3812

nrc3144

nature03445

10.1038/nature03443

molcel.2010.06.017

Pharmacological Reviews. 2002;**54**(3):375-429

2006;**7**(3):165-172. DOI: 10.1016/j.carrev.2006.02.002

[12] Komatsu M, Sumizawa T, Mutoh M, Chen ZS, Terada K, Furukawa T, Yang XL, Gao H, Miura N, Sugiyama T, Akiyama S. Copper-transporting P-type adenosine triphosphatase (ATP7B) is associated with cisplatin resistance. Cancer Research. 2000;**60**(5):1312-1316

**Author details**

162 Cancer Management and Therapy

**References**

2006.03.012

**9**(16 Pt 1):5853-5859

Arkene Levy\* and Patricia C. Rose

\*Address all correspondence to<EMAIL_ADDRESS>
2017;**67**(1):7-30. DOI: 10.3322/caac.21387

x111-x117. DOI: 10.1093/annonc/mds300

2002;**20**:1158-1160. DOI: 10.1200/JCO.2<IP_ADDRESS>8

cancer. Chemotherapy. 2005;**51**:347-351. DOI: 10.1159/000088959

2016;**116**(5):3436-3486. DOI: 10.1021/acs.chemrev.5b00597

drugs—Phenanthriplatin. Anticancer Research. 2014;**34**(1):471-476

2001;**478**(1-2):23-43. DOI: https://doi.org/10.1016/S0027-5107(01)00141-5

2529. DOI: 10.1056/NEJMra041842

Medicine and Biology. 1977;**91**:129-150

[1] Siegel RL, Miller KD, Jemal A. Cancer statistics, 2017. CA: A Cancer Journal for Clinicians.

[2] Prat J. New insights into ovarian cancer pathology. Annals of Oncology. 2012;**23**(suppl 10):

[3] Cannistra SA. Cancer of the ovary. The New England Journal of Medicine. 2004;**351**:2519-

[4] Pfisterer J, Ledermann JA. Management of platinum-sensitive recurrent ovarian cancer. Seminars in Oncology. 2006;**33**(suppl 6):12-16. DOI: https://doi.org/10.1053/j.seminoncol.

[5] Cannistra SA. Is there a "best" choice of second-line agent in the treatment of recurrent, potentially platinum-sensitive ovarian cancer? Journal of Clinical Oncology.

[6] Karabulut B, Sezgin C, Terek M, et al. Topotecan in platinum-resistant epithelial ovarian

[7] Rosenberg B. Noble metal complexes in cancer chemotherapy. Advances in Experimental

[8] Johnstone TC, Suntharalingam K, Lippard SJ. The next generation of platinum drugs: Targeted Pt(II) agents, nanoparticle delivery, and Pt(IV) prodrugs. Chemical Review.

[9] Johnstone TC, Park GY, Lippard SJ. Understanding and improving platinum anticancer

[10] Kartalou M, Essigmann J. Mechanisms of resistance to cisplatin. Mutation Research.

[11] Samimi G, Varki NM, Wilczynski S, Safaei R, Alberts DS, Howell SB. Increase in expression of the copper transporter ATP7A during platinum drug-based treatment is associated with poor survival in ovarian cancer patients. Clinical Cancer Research. 2003;

Nova Southeastern University, Florida, USA

[24] Coward JI, Middleton K, Murphy F. New perspectives on targeted therapy in ovarian cancer. International Journal of Women's Health. 2015;**7**:189-203. DOI: http://doi. org/10.2147/IJWH.S52379

[36] Burger RA, Sill MW, Monk BJ, Greer BE, Sorosky JI. Phase II trial of bevacizumab in persistent or recurrent epithelial ovarian cancer or primary peritoneal cancer: A gynecologic oncology group study. Journal of Clinical Oncology. 2007;**25**(33):5165-5171. DOI:

Targeted Therapies in Platinum-Resistant Ovarian Cancer: Advances in Immunotherapy…

http://dx.doi.org/10.5772/intechopen.72017

165

[37] Pujade-Lauraine E et al. Bevacizumab combined with chemotherapy for platinumresistant recurrent ovarian cancer: The AURELIA open-label randomized phase III trial.

[38] Musa F, et al. Phase II study of irinotecan in combination with bevacizumab in recurrent ovarian cancer. Gynecologic Oncology 2017;**144**(2):279-284. DOI: http://dx.doi.

[39] Dinkic C et al. Pazopanib (GW786034) and cyclophosphamide in patients with platinum-resistant, recurrent, pre-treated ovarian cancer—Results of the PACOVAR-trial.

[40] Hashimoto K, Man S, Xu P, Cruz-Munoz W, Tang T, Kumar R, Kerbel RS. Potent preclinical impact of metronomic low-dose oral topotecan combined with the antiangiogenic drug pazopanib for the treatment of ovarian cancer. Molecular Cancer Therapeutics.

[41] Kumaran GC, Jayson GC, Clamp AR. Antiangiogenic drugs in ovarian cancer. British

[42] Fraser HM, Wilson H, Rudge JS, Wiegand SJ. Single injections of vascular endothelial growth factor trap block ovulation in the macaque and produce a prolonged, doserelated suppression of ovarian function. The Journal of Clinical Endocrinology and

[43] Tew WP, Colombo N, Ray-Coquard I, del Campo JM, Oza A, Pereira D, Mammoliti S, et al. Intravenous aflibercept in patients with platinum-resistant, advanced ovarian cancer: Results of a randomized, double-blind, phase II, parallel-arm study. Cancer.

[44] Schaller MD, Borgman CA, Cobb BS, Vines RR, Reynolds AB, Parsons JT. pp125FAK a structurally distinctive protein-tyrosine kinase associated with focal adhesions. Proceedings of the National Academy of Sciences of the United States of America.

[45] Hungerford JE, Compton MT, Matter ML, Hoffstrom BG, Otey CA. Inhibition of pp125FAK in cultured fibroblasts results in apoptosis. The Journal of Cell Biology.

[46] Frisch SM, Vuori K, Ruoslahti E, Chan-Hui PY. Control of adhesion-dependent cell survival by focal adhesion kinase. The Journal of Cell Biology. 1996;**134**:793-799

[47] Sood AK, Coffin JE, Schneider GB, Fletcher MS, DeYoung BR, Gruman LM, Gershenson DM, Schaller MD, Hendrix MJC. Biological significance of focal adhesion kinase in ovarian

Gynecologic Oncology. 2017;**146**(2):279-284. DOI: 10.1016/j.ygyno.2017.05.013

2010;**9**(4):996-1006. DOI: 10.1158/1535-7163.MCT-09-0960

Metabolism. 2005;**90**:1114-1122. DOI: 10.1210/jc.2004-1572

2014;**120**:335-343. DOI: 10.1002/cncr.28406

1992;**89**:5192-5196

1996;**135**:1383-1390

Journal of Cancer. 2009;**100**(1):1-7. DOI: 10.1038/sj.bjc.6604767

Journal of Clinical Oncology. 2014;**32**:1302-1308. DOI: 10.1200/JCO.2013.51.4489

10.1200/JCO.2007.11.5345

org/10.1016/j.ygyno.2016.11.043

[36] Burger RA, Sill MW, Monk BJ, Greer BE, Sorosky JI. Phase II trial of bevacizumab in persistent or recurrent epithelial ovarian cancer or primary peritoneal cancer: A gynecologic oncology group study. Journal of Clinical Oncology. 2007;**25**(33):5165-5171. DOI: 10.1200/JCO.2007.11.5345

[24] Coward JI, Middleton K, Murphy F. New perspectives on targeted therapy in ovarian cancer. International Journal of Women's Health. 2015;**7**:189-203. DOI: http://doi.

[25] Murai J, Huang SY, Das BB, et al. Trapping of PARP1 and PARP2 by clinical PARP inhibitors. Cancer Research. 2012;**72**(21):5588-5599. DOI: 10.1158/0008-5472.CAN-12-2753 [26] Munroe M, Kolesar J. Olaparib for the treatment of BRCA-mutated advanced ovarian cancer. American Journal of Health-System Pharmacy. 2016;**73**(14):1037-1041. DOI:

[27] Oza AM, Tinker AV, Oaknin A, Shapira-Frommer R, McNeish IA, Swisher EM, Ray-Coquard I, Bell-McGuinn K, et al. Antitumor activity and safety of the PARP inhibitor rucaparib in patients with high-grade ovarian carcinoma and a germline or somatic BRCA1 or BRCA2 mutation: Integrated analysis of data from Study 10 and ARIEL2. Gynecologic

[28] Sandhu SK, Schelman WR, Wilding G, et al. The poly(ADP-ribose) polymerase inhibitor niraparib (MK4827) in BRCA mutation carriers and patients with sporadic cancer: A phase 1 dose-escalation trial. The Lancet Oncology. 2013;**14**(9):882-892. DOI: 10.1016/

[29] Issaeva N et al. 6-thioguanine selectively kills BRCA2-defective tumors and overcomes PARP inhibitor resistance. Cancer Research. 2010;**70**:6268-6276. DOI: 10.1158/0008-5472.

[30] Lord CJ, Ashworth A. Mechanisms of resistance to therapies targeting BRCA-mutant

[31] Spannuth WA, Nick AM, Jennings NB, Armaiz-Pena GN, Mangala LS, Danes CG, Lin YG, Merritt WM, Thaker PH, Kamat AA, Han LY, Tonra JR, Coleman RL, Ellis LM, Sood AK. Functional significance of VEGFR-2 on ovarian cancer cells. International Journal of

[32] Shweiki D, Itin A, Soffer D, Keshet E. Vascular endothelial growth factor induced by hypoxia may mediate hypoxia initiated angiogenesis. Nature. 1992;**359**:843-845. DOI:

[33] Wong C, Wellman TL, Lounsbury KM. VEGF and HIF-1 alpha expression are increased in advanced stages of epithelial ovarian cancer. Gynecologic Oncology. 2003;**91**:513-517

[34] Avril S et al. Increased PDGFR-beta and VEGFR-2 protein levels are associated with resistance to platinum-based chemotherapy and adverse outcome of ovarian cancer patients. Oncotarget. 2017. Available from: https://doi.org/10.18632/oncotarget.18415

[35] Chase DM, Chaplin DJ, Monk BJ. The development and use of vascular targeted therapy in ovarian cancer. Gynecologic Oncology 2017;**145**:393-406. DOI: http://dx.doi.

cancers. Nature Medicine. 2013;**19**(11):1381-1388. DOI: 10.1038/nm.3369

Cancer. 2009;**124**(5):1045-1053. DOI: 10.1002/ijc.24028

Oncology. 2017; pii: S0090-8258(17)31260-X. DOI: 10.1016/j.ygyno.2017.08.022

org/10.2147/IJWH.S52379

164 Cancer Management and Therapy

10.2146/ajhp150550

S1470-2045(13)70240-7

CAN-09-3416

10.1038/359843a0

[Accessed: September 12, 2017]

org/10.1016/j.ygyno.2017.01.031

cancer: Role in migration and invasion. American Journal of Pathology. 2004;**165**:1087- 1095. DOI: 10.1016/S0002-9440(10)63370-6

[58] Dosio F, Milla P, Cattel L. EC-145, a folate-targeted vinca alkaloid conjugate for the potential treatment of folate receptor-expressing cancers. Current Opinion in Investigational

Targeted Therapies in Platinum-Resistant Ovarian Cancer: Advances in Immunotherapy…

http://dx.doi.org/10.5772/intechopen.72017

167

[59] Naumann W, Coleman R, Robert A, Burger R, Sausville E, Kutarska E, Ghamande S, Gabrail N, DePasquale S, et al. PRECEDENT: A randomized phase II trial comparing vintafolide (EC145) and pegylated liposomal doxorubicin (PLD) in combination versus PLD alone in patients with platinum-resistant ovarian cancer. Journal of Clinical

[60] Yunusova NV, Villert AB, Spirina LV, Frolova AE, Kolomiets LA, Kondakova IV. Insulinlike growth factors and their binding proteins in tumors and ascites of ovarian cancer patients: Association with response to Neoadjuvant chemotherapy. Asian Pacific Journal of Cancer Prevention. 2016;**17**(12):5315-5320. DOI: http://doi.org/10.22034/APJCP.2016.17.

[61] Shao M, Hollar S, Chambliss D, Schmitt J, Emerson R, Chelladurai B, et al. Targeting the insulin growth factor and the vascular endothelial growth factor pathways in ovarian cancer. Molecular Cancer Therapeutics. 2012;**11**:1576-1586. DOI: 10.1158/1535-7163.

[62] Gotlieb WH, Bruchim I, Gu J, Shi Y, Camirand A, Blouin MJ, et al. Insulin-like growth factor receptor I targeting in epithelial ovarian cancer. Gynecologic Oncology. 2006;**100**:389-

[63] Beauchamp MC, Yasmeen A, Knafo A, Gotlieb WH. Targeting insulin and insulin-like growth factor pathways in epithelial ovarian cancer. Journal of Oncology.

[64] A Phase Ib/II Study of the Combination of BYL719 Plus AMG 479 in Adult Patients With Selected Solid Tumors. Available from: http://clinicaltrials.gov/show/ NCT01708161.

[65] Harb WA, Sessa C, Hirte HW, Kaye SB, Banerjee SN, Christinat A, et al. Final results of a phase I study evaluating the combination of linsitinib, a dual inhibitor of insulinlike growth factor-1 receptor (IGF-1R), and insulin receptor (IR) with weekly paclitaxel (PAC) in patients (Pts) with advanced solid tumors. Journal of Clinical Oncology.

[66] Teplinsky E, Muggia F. EGFR and HER2: Is there a role in ovarian cancer? Translational Cancer Research. 2015;**4**(1):107-117. DOI: 10.3978/j.issn.2218-676X.2015.01.01

[67] Siwak DR, Carey M, Hennessy BT, et al. Targeting the epidermal growth factor receptor in epithelial ovarian cancer: Current knowledge and future challenges. Journal of

[68] Kurzeder C, Bover I, Marme F, et al. Double-blind, placebo-controlled, randomized phase III trial evaluating pertuzumab combined with chemotherapy for low tumor

2013;**31**(15\_suppl):e13502-e13502. DOI: 10.1200/jco.2013.31.15\_suppl.e13502

Oncology. 2013;**31**(35):4400-4406. DOI: 10.1200/JCO.2013.49.7685

Drugs. 2010;**11**(12):1424-1433

12.5315

MCT-11-0961

396. DOI: 10.1016/j.ygyno.2005.09.048

2010;**2010**:257058. DOI: 10.1155/2010/257058

Oncology. 2010;**2010**. DOI: 10.1155/2010/568938

NLM identifier: NCT01708161 [Accessed: September 1, 2017]

[58] Dosio F, Milla P, Cattel L. EC-145, a folate-targeted vinca alkaloid conjugate for the potential treatment of folate receptor-expressing cancers. Current Opinion in Investigational Drugs. 2010;**11**(12):1424-1433

cancer: Role in migration and invasion. American Journal of Pathology. 2004;**165**:1087-

[48] Bonome T, Lee JY, Park DC, et al. Expression profiling of serous low malignant potential, low-grade, and high-grade tumors of the ovary. Cancer Research. 2005;**65**:10602-10612.

[49] Ward KK, Tancioni I, Lawson C, Miller NLG, Jean C, Chen XL, et al. Inhibition of focal adhesion kinase (FAK) activity prevents anchorage-independent ovarian carcinoma cell growth and tumor progression. Clinical & Experimental Metastasis. 2013;**30**(5):579-594.

[50] Fraser M, Leung B, Jahani-Asl A, Yan X, Thompson WE, Tsang BK. Chemoresistance in human ovarian cancer: The role of apoptotic regulators. Reproductive Biology and

[51] Jones SF, Siu LL, Bendell JC, et al. Investigational New Drugs. 2015;**33**:1100. DOI: 10.1007/

[52] Patel MR, Infante JR, Moore KN, Keegan M, Poli A, Padval M, Fields Jones S, Horobin J, Burris HA. Phase I/Ib study of the FAK inhibitor defactinib (VS-6063) in combination with weekly paclitaxel for advanced ovarian cancer. In: Proceedings of the AACR-NCI-EORTC International Conference: Molecular Targets and Cancer Therapeutics (AACR 2013); 19-23 October 2013; Boston, MA. Philadelphia (PA). Molecular Cancer

[53] Soria JC, Gan HK, Blagden SP, Plummer R, Arkenau HT, Ranson M, Evans TRJ, Zalcman G, Bahleda R, et al. A phase I, pharmacokinetic and pharmacodynamic study of GSK2256098, a focal adhesion kinase inhibitor, in patients with advanced solid tumors. Annals of

[54] Wu M, Fan J, Gunning W, Ratnam M. Clustering of GPI-anchored folate receptor independent of both cross-linking and association with caveolin. The Journal of Membrane

[55] Serpe L, Gallicchio M, Canaparo R, Dosio F. Targeted treatment of folate receptorpositive platinum-resistant ovarian cancer and companion diagnostics, with specific focus on vintafolide and etarfolatide. Pharmacogenomics and Personalized Medicine.

[56] Chen Y-L, Chang M-C, Huang C-Y, et al. Serous ovarian carcinoma patients with high alpha-folate receptor had reducing survival and cytotoxic chemo-response. Molecular

[57] Morphotek—An efficacy and safety study of MORAb-003 in platinum-resistant or refractory relapsed ovarian cancer (FAR-122). Available from: http://clinicaltrials.gov/ show/NCT00738699. NLM identifier: NCT00738699. [Accessed: September 1, 2017]

1095. DOI: 10.1016/S0002-9440(10)63370-6

DOI: 10.1158/0008-5472.CAN-05-2240

s10637-015-0282-y

166 Cancer Management and Therapy

Biology. 1997;**159**(2):137-147

2014;**7**:31-42. DOI: 10.2147/PGPM.S58374

DOI: http://doi.org/10.1007/s10585-012-9562-5

Endocrinology. 2003;**1**:66. DOI: 10.1186/1477-7827-1-66

Therapeutics. 2013;**12**(11 Suppl):Abstract nr A69

Oncology. 2016;**27**(12):2268-2274. DOI: 10.1093/annonc/mdw427

Oncology. 2012;**6**(3):360-369. DOI: 10.1016/j.molonc.2011.11.010

human epidermal growth factor receptor 3 mRNA-expressing platinum-resistant ovarian cancer (PENELOPE). Journal of Clinical Oncology. 2016;**34**:2516-2525. DOI: 10.1200/JCO.2015.66.0787

[79] Di Giacomoa AM, Biagiolib M, Maioa M. The emerging toxicity profiles of anti-CTLA-4 antibodies. Seminars in Oncology. 2010;**37**(5):499-507. DOI: 10.1053/j.seminoncol.2010.

Targeted Therapies in Platinum-Resistant Ovarian Cancer: Advances in Immunotherapy…

http://dx.doi.org/10.5772/intechopen.72017

169

[80] Chester C, Dorigo O, Berek J, Kohrt H. Immunotherapeutic approaches to ovarian cancer treatment. Journal for Immunotherapy of Cancer. 2015;**3**:7. DOI: https://doi.org/10.1186/

[81] Gray H, Gargosky S. Progression-free survival in ovarian cancer patients in second remission with mucin-1 autologous dendritic cell therapy. Abstract #5504. Oral Presentation,

[82] Mitchell P, Quinn M, Grant P, Allen D, Jobling T, White S, Zhao A, Karanikas V, Vaughan H, Pietersz G, McKenzie I, Gargosky S, Loveland BE. A phase II, singlearm study of an autologous dendritic cell treatment against mucin 1 in patients with advanced epithelial ovarian cancer. Journal for Immunotherapy of Cancer. 2015;**2**:16.

[83] hiang CL, Kandalaft LE, Tanyi J, Hagemann AR, Motz GT, Svoronos N, et al. A dendritic cell vaccine pulsed with autologous hypochlorous acid-oxidized ovarian cancer lysate primes effective broad antitumor immunity: From bench to bedside. Clinical Cancer

[84] Sabbatini P, Tsuji T, Ferran L, Ritter E, Sedrak C, Tuballes K, et al. Phase I trial of overlapping long peptides from a tumor self-antigen and poly-ICLC shows rapid induction of integrated immune response in ovarian cancer patients. Clinical Cancer Research.

[85] Reinartz S, Köhler S, Schlebusch H, Krista K, Giffels P, Renke K, et al. Vaccination of patients with advanced ovarian carcinoma with the anti-idiotype ACA125: Immunological response and survival (phase Ib/II). Clinical Cancer Research. 2004;**10**:1580-1587. DOI:

[86] Mohebtash M, Tsang KY, Madan RA, Huen NY, Poole DJ, Jochems C, et al. A pilot study of MUC-1/CEA/TRICOM poxviral-based vaccine in patients with metastatic breast and ovarian cancer. Clinical Cancer Research. 2011;**17**:7164-7173. DOI: 10.1158/1078-0432.

[87] Engelstaedter V, Heublein S, Schumacher AL, Lenhard M, Engelstaedter H, Andergassen U, et al. Mucin-1 and its relation to grade, stage and survival in ovarian carcinoma patients.

[88] Yurkovetsky Z, Skates S, Lomakin A, Nolen B, Pulsipher T, Modugno F, Marks J, Godwin A, Gorelik E, Jacobs I, Menon U, Lu K, Badgwell D, Bast RC Jr, Lokshin AE. Development of a multimarker assay for early detection of ovarian cancer. Journal of Clinical Oncology

BMC Cancer. 2012;**12**:600. DOI: https://doi.org/10.1186/1471-2407-12-600

Research. 2013;**9**:4801-4815. DOI: 10.1158/1078-0432.CCR-13-1185

2012;**18**:6497-6508. DOI: 10.1158/1078-0432.CCR-12-2189

2010;**28**(13):2159-2166. DOI: 10.1200/JCO.2008.19.2484

09.007

s40425-015-0051-7

ASCO Annual Meeting. 2014

DOI: 10.1186/2051-1426-2-16

10.1158/1078-0432.CCR-03-0056

CCR-11-0649

[79] Di Giacomoa AM, Biagiolib M, Maioa M. The emerging toxicity profiles of anti-CTLA-4 antibodies. Seminars in Oncology. 2010;**37**(5):499-507. DOI: 10.1053/j.seminoncol.2010. 09.007

human epidermal growth factor receptor 3 mRNA-expressing platinum-resistant ovarian cancer (PENELOPE). Journal of Clinical Oncology. 2016;**34**:2516-2525. DOI:

[69] Khalil DN, Smith EL, Brentjens RJ, Wolchok JD. The future of cancer treatment: Immunomodulation, CARs and combination immunotherapy. Nature Reviews. Clinical

[70] Pardoll DM. The blockade of immune checkpoints in cancer immunotherapy. Nature

[71] Gaillard SL, Secord AA, Monk B. The role of immune checkpoint inhibition in the treatment of ovarian cancer. Gynecologic Oncology Research and Practice. 2016;**3**:11. DOI:

[72] Eng KH, Weir I, Tsuji T, Odunsi K. Immuno-stimultory/regulatory gene expression patterns in advanced ovarian cancer. Genes & Cancer. 2015;**6**(9-10):399-407. DOI: 10.18632/

[73] Heong V, Ngoi N, Tan DSP. Update on immune checkpoint inhibitors in gynecological cancers. Journal of Gynecologic Oncology. 2017;**28**(**2**):e20. DOI: 10.3802/jgo.2017.28.e20

[74] Hamanishi J et al. Efficacy and safety of anti-PD-1 antibody (Nivolumab: BMS-936558, ONO-4538) in patients with platinum resistant ovarian cancer. Journal of Clinical

[75] Disis ML, Patel MR, Pant S, Infante JR, Lockhart AC, Kelly K, et al. Avelumab (MSB0010718 C), an anti-PD-L1 antibody, in patients with previously treated, recurrent or refractory ovarian cancer: A phase Ib, open-label expansion trial. Asco Meet Abstr.

[76] Varga A, Piha-Paul SA, Ott PA, Mehnert JM, Berton-Rigaud D, Johnson EA, et al. Antitumor activity and safety of pembrolizumab in patients (pts) with PD-L1 positive advanced ovarian cancer: Interim results from a phase Ib study. Asco Meet Abstr.

[77] Hodi FS, Mihm MC, Soiffer RJ, Haluska FG, Butler M, Seiden MV, Davis T, Henry-Spires R, MacRae S, Willman A, Padera R, Jaklitsch MT, Shankar S, Chen TC, Korman A, Allison JP, Dranoff G. Biologic activity of cytotoxic T lymphocyte-associated antigen 4 antibody blockade in previously vaccinated metastatic melanoma and ovarian carcinoma patients. Proceedings of the National Academy of Sciences of the United States of

[78] Callahan MK. A phase I study to evaluate the safety and tolerability of MEDI4736, an anti-PD-L1 antibody, in combination with tremelimumab in patients with advanced solid tumors. In: Proceedings of the ASCO Annual Meeting, 2014, http://meetinglibrary.

Oncology. 2014;**32**(suppl):5511. DOI: 10.1200/jco.2014.32.15\_suppl.5511

Oncology. 2016;**13**:273-290. DOI: 10.1038/nrclinonc.2016.25

Reviews. Cancer. 2012;**12**:252-264. DOI: 10.1038/nrc3239

https://doi.org/10.1186/s40661-016-0033-6

10.1200/JCO.2015.66.0787

168 Cancer Management and Therapy

genesandcancer

2015;**33**(suppl 15):5509

2015;**33**(suppl 15):5510

America. 2003 Apr 15;**100**(8):4712-4717

asco.org/content/130062-144

[89] Drerup JM, Liu Y, Padron AS, Murthy K, Hurez V, Zhang B, Curiel TJ. Immunotherapy for ovarian cancer. Current Treatment Options in Oncology. 2015;**16**(1):317. DOI: http:// doi.org/10.1007/s11864-014-0317-1

**Chapter 8**

**Provisional chapter**

**Breast and Axilla Treatment in Ductal Carcinoma In Situ**

Ductal carcinoma in situ (DCIS) represents a challenge for the breast unit team, beginning from its difficult radiological detection and continuing with its controversial multimodal treatment and management. With the introduction of the mammographic screening, DCIS has become a common diagnosis. In fact, today DCIS is mostly identified by mammography or magnetic resonance imaging (MRI). The increased prevalence of DCIS diagnosis, in the past, raised the problem of the therapeutic management. In this chapter, the breast and axillary surgery in case of DCIS and the most controversial aspects regarding DCIS management are reviewed based on international guidelines and

**Keywords:** ductal carcinoma in situ, ductal intraepithelial neoplasia, breast-conserving

Ductal carcinoma in situ (DCIS) represents a current challenge for the breast specialists, beginning from its difficult radiological detection and continuing with its controversial surgical and nonsurgical management. In this chapter, breast surgery and axillary surgery in case of DCIS are reviewed, as well as some aspects of its preoperative evaluation, based on the

more recent international guidelines, and the controversial issues are discussed.

surgery, sentinel lymph node biopsy, breast cancer, breast surgery

**Breast and Axilla Treatment in Ductal Carcinoma In**

© 2016 The Author(s). Licensee InTech. This chapter is distributed under the terms of the Creative Commons Attribution License (http://creativecommons.org/licenses/by/3.0), which permits unrestricted use, distribution, and reproduction in any medium, provided the original work is properly cited.

© 2018 The Author(s). Licensee IntechOpen. This chapter is distributed under the terms of the Creative Commons Attribution License (http://creativecommons.org/licenses/by/3.0), which permits unrestricted use,

distribution, and reproduction in any medium, provided the original work is properly cited.

DOI: 10.5772/intechopen.74340

Ambrogio P. Londero, Serena Bertozzi,

Ambrogio P. Londero, Serena Bertozzi,

Laura Mariuzzi and Carla Cedolini

Laura Mariuzzi and Carla Cedolini

**Situ**

http://dx.doi.org/10.5772/intechopen.74340

on the current literature.

**Abstract**

**1. Introduction**

Roberta Di Vora, Fabrizio De Biasio, Luca Seriau, Pier Camillo Parodi, Lorenza Driul, Andrea Risaliti,

Roberta Di Vora, Fabrizio De Biasio, Luca Seriau, Pier Camillo Parodi, Lorenza Driul, Andrea Risaliti,

Additional information is available at the end of the chapter

Additional information is available at the end of the chapter

**Chapter 8 Provisional chapter**

#### **Breast and Axilla Treatment in Ductal Carcinoma In Situ Breast and Axilla Treatment in Ductal Carcinoma In**

DOI: 10.5772/intechopen.74340

Ambrogio P. Londero, Serena Bertozzi, Roberta Di Vora, Fabrizio De Biasio, Luca Seriau, Pier Camillo Parodi, Lorenza Driul, Andrea Risaliti, Laura Mariuzzi and Carla Cedolini Ambrogio P. Londero, Serena Bertozzi, Roberta Di Vora, Fabrizio De Biasio, Luca Seriau, Pier Camillo Parodi, Lorenza Driul, Andrea Risaliti, Laura Mariuzzi and Carla Cedolini

Additional information is available at the end of the chapter Additional information is available at the end of the chapter

http://dx.doi.org/10.5772/intechopen.74340

#### **Abstract**

**Situ**

[89] Drerup JM, Liu Y, Padron AS, Murthy K, Hurez V, Zhang B, Curiel TJ. Immunotherapy for ovarian cancer. Current Treatment Options in Oncology. 2015;**16**(1):317. DOI: http://

[90] Wright SE, Rewers-Felkins KA, Quinlin IS, Phillips CA, Townsend M, Philip R, Dobrzanski MJ, Lockwood-Cooke PR, Robinson W. Cytotoxic T-lymphocyte immunotherapy for ovarian cancer: A pilot study. Journal of Immunotherapy. 2012; Feb-

[91] Kandalaft LE, Powell DJ, Coukos G. A phase I clinical trial of adoptive transfer of folate receptor-alpha redirected autologous T cells for recurrent ovarian cancer. Journal of

[92] Monk BJ, Brady MF, Aghajanian C, Lankes HA, Rizack T, Leach J, Fowler JM, Higgins R, et al. A phase II, randomized, double-blind, placebo-controlled study of chemo-immunotherapy combination using motolimod with pegylated liposomal doxorubicin in recurrent or persistent ovarian cancer: A gynecologic oncology group partners study.

[93] De Felice F, Marchetti C, Palaia I, Musio D, Muzii L, Tombolini V, Panici PB. Immunotherapy of ovarian cancer: The role of checkpoint inhibitors. Journal of Immunology

[94] Konstantinopoulos P, Moore K, Sachdev J, Mita M, Vinayak S, Seward S, et al. Phase I/II study of niraparib plus pembrolizumab in patients with triple-negative breast cancer or recurrent ovarian cancer (KEYNOTE-162). Journal of Clinical Oncology. 2016;**34** abstract

[95] Hodi FS, Butler M, Oble DA, Seiden MV, Haluska FG, Kruse A, et al. Immunologic and clinical effects of antibody blockade of cytotoxic T lymphocyte-associated antigen 4 in previously vaccinated cancer patients. Proceedings of the National Academy of Sciences.

Annals of Oncology. 01-05-2017;**28**(5):996-1004. DOI: 10.1093/annonc/mdx049

doi.org/10.1007/s11864-014-0317-1

170 Cancer Management and Therapy

TPS5599

Mar;**35**(2):196-204. DOI: 10.1097/CJI.0b013e318243f213

Translational Medicine. 2012;**10**:157. DOI: 10.1186/1479-5876-10-157

Research 2015; 2015. DOI: http://dx.doi.org/10.1155/2015/191832

2008;**105**:3005-3010. DOI: 10.1073/pnas.0712237105

Ductal carcinoma in situ (DCIS) represents a challenge for the breast unit team, beginning from its difficult radiological detection and continuing with its controversial multimodal treatment and management. With the introduction of the mammographic screening, DCIS has become a common diagnosis. In fact, today DCIS is mostly identified by mammography or magnetic resonance imaging (MRI). The increased prevalence of DCIS diagnosis, in the past, raised the problem of the therapeutic management. In this chapter, the breast and axillary surgery in case of DCIS and the most controversial aspects regarding DCIS management are reviewed based on international guidelines and on the current literature.

 Introduction**

Ductal carcinoma in situ (DCIS) represents a current challenge for the breast specialists, beginning from its difficult radiological detection and continuing with its controversial surgical and nonsurgical management. In this chapter, breast surgery and axillary surgery in case of DCIS are reviewed, as well as some aspects of its preoperative evaluation, based on the more recent international guidelines, and the controversial issues are discussed.

© 2016 The Author(s). Licensee InTech. This chapter is distributed under the terms of the Creative Commons Attribution License (http://creativecommons.org/licenses/by/3.0), which permits unrestricted use, distribution, and reproduction in any medium, provided the original work is properly cited. © 2018 The Author(s). Licensee IntechOpen. This chapter is distributed under the terms of the Creative Commons Attribution License (http://creativecommons.org/licenses/by/3.0), which permits unrestricted use, distribution, and reproduction in any medium, provided the original work is properly cited.

## **2. Histopathological aspects**

The breast gland contains a ductal system that, with successive branches, ends distally in the terminal ductal-lobular units. Ducts and lobules are coated with two types of cells: luminal epithelial cells and myoepithelial cells. The myoepithelial cells contain myofilaments, have contractile capacity, and form a network structure located on the basal membrane. Histologically, the retention of the myoepithelial cell layer helps to distinguish in situ forms from invasive ones.

originate from in situ forms is difficult to demonstrate, despite the many studies that have tried different approaches to achieve this. In particular, some studies focused on women with untreated DCIS, and some others used animals, as well as genomic studies of expression of

Breast and Axilla Treatment in Ductal Carcinoma In Situ http://dx.doi.org/10.5772/intechopen.74340 173

DCIS greatly differs from benign proliferative breast lesions for its biological and clinical features. Alterations in the normal number of chromosomes occur in the evolution of breast lesions from benign hyperplasia to preinvasive malignant forms [4]. Heterozygosis lost occurs in more than 70% of high-grade DCIS, in 35–40% of atypical ductal hyperplasia, and in 0% of normal mammary tissue samples [5–7]. The p53 oncosuppressor gene is mutated in 25% of DCIS and only rarely in benign breast lesions [8]. Genomic analyses identified some genetic alterations related to the nuclear grading of DCIS [9]: loss of genetic material in the chromosome 16q resulted associated with well or moderately differentiated DCIS, while DNA amplifications were related to a poorer differentiation. Thereafter, the genetic characteristics of DCIS were also compared with those of the adjacent invasive cell carcinomas, showing

Several other studies reported genetic similarities between invasive carcinoma and DCIS, especially high-grade DCIS, supporting the hypothesis that invasive carcinomas derive from the progression of preexisting DCIS [4, 10, 11]. The first step might be the abnormal response to growth factors, for example, mediated by estrogen receptors, which let the benign cells lose their ability to respond to normal apoptosis signals. Then, there would be the loss of function of some oncosuppressor genes as p53, the acquisition of some genetic instability with the loss of heterozygosity, and the onset of abnormal oncogenes such as HER2/neu. Finally, also changes in the surrounding stroma and neoangiogenesis occur, so that the preinvasive lesion becomes capable of invading the surrounding tissues for an imbalance between the gain of

Many of the typical molecular characteristics of invasive lesions are already present in DCIS, such as genetic mutations, oncogenic expression, and loss of normal cell cycle regulation ability. The expression of molecular markers seems to have many points in common between in situ and invasive ductal carcinoma, supporting again the evolution of invasive carcinoma

The estrogen receptor is expressed in about 60% of DCIS [1] especially in those that exhibit less aggressive histological features such as low grading of differentiation and necrosis. The progesterone receptor expression seems to be consensual to that of the estrogen receptor.

HER2/neu is a member of the epidermal growth factor receptor (EGFR) family and is routinely studied in invasive carcinomas. It seems to be expressed by more than 40% of DCIS, especially by high-grade or comedogenic ones [12], so it would appear to be expressed in

The expression of markers differs according to the nuclear grading of DCIS. In fact, considering only low-grade DCIS, some studies showed that in over 90% of cases it expresses the estrogen receptor, while in less than 20% of cases, it overexpresses HER2/neu or presents p53

function by malignant cells and loss of function by the surrounding normal cells.

from DCIS. In the following section, these markers are discussed.

these lesions with a much higher frequency than that of invasive forms.

cellular markers.

almost identical patterns.

**2.2. Biomolecular markers**

DCIS is a neoplastic breast lesion, characterized by the presence in the ductal-lobular terminal unit of a malignant epithelial cell clone that does not exceed the basal membrane. DCIS includes a spectrum of different lesions from the histological point of view, with different architecture, nuclear morphology, degree, and the eventual presence of necrosis and calcifications.

DCIS has been historically divided into five histological subtypes, based on the tumor cell growth modality: comedogenic, solid, cribriform, papillary, and micropapillary; however, in most cases the appearance is composite.

Comedogenic DCIS is characterized by a solid proliferation of large pleomorphic cells, with abundant eosinophilic cytoplasm and high-grade hyperchromatic nuclei. A peculiar aspect of this DCIS is the presence of central necrosis which may give place to dystrophic calcifications, which are usually detected by mammography as clustered microcalcifications. Frequently, these lesions contain periductal fibrosis, due to the fibroblast response in the surrounding stroma, and a chronic inflammation component which may sometimes make these lesions clinically palpable.

Noncomedogenic DCIS consists of a population of smaller and monomorphic neoplastic cells, with variable nuclear grading. Necrosis is minimal or absent and the periductal fibrosis is unfrequent. In the cribriform subtype, neoformed glandular spaces are uniformly distributed and have a regular shape. In the solid DCIS, neoplastic cells completely fill in the interested tissue. The papillary subtype grows, giving rise to papillary formations with the fibrovascular axis missing in the micropapillary DCIS, also characterized by interstitial papillary protrusions.

The importance of this morphological classification has been downsized in recent years since this distinction does not take into account important prognostic factors such as nuclear grading, necrosis, and architecture [1, 2]. However, a distinction between comedogenic and noncomedogenic DCIS remains very significant, because of the poorer prognosis of the comedogenic type, which is at higher risk of evolution toward invasive carcinoma and of local recurrence [3].

Several classifications were subsequently proposed [1], taking into consideration nuclear grading, presence of necrosis, histological architecture and pattern, lesion size, number of involved ducts, cell polarization, and positivity for some receptors. The most used classification systems are those endowed with prognostic power.

#### **2.1. Natural history**

Several recent studies have shown that invasive breast cancer results from a progression of in situ cancer that proliferates and increases to overcome the basal membrane of the ductal epithelium, thus becoming infiltrating. However, the probability that all invasive carcinomas originate from in situ forms is difficult to demonstrate, despite the many studies that have tried different approaches to achieve this. In particular, some studies focused on women with untreated DCIS, and some others used animals, as well as genomic studies of expression of cellular markers.

DCIS greatly differs from benign proliferative breast lesions for its biological and clinical features. Alterations in the normal number of chromosomes occur in the evolution of breast lesions from benign hyperplasia to preinvasive malignant forms [4]. Heterozygosis lost occurs in more than 70% of high-grade DCIS, in 35–40% of atypical ductal hyperplasia, and in 0% of normal mammary tissue samples [5–7]. The p53 oncosuppressor gene is mutated in 25% of DCIS and only rarely in benign breast lesions [8]. Genomic analyses identified some genetic alterations related to the nuclear grading of DCIS [9]: loss of genetic material in the chromosome 16q resulted associated with well or moderately differentiated DCIS, while DNA amplifications were related to a poorer differentiation. Thereafter, the genetic characteristics of DCIS were also compared with those of the adjacent invasive cell carcinomas, showing almost identical patterns.

Several other studies reported genetic similarities between invasive carcinoma and DCIS, especially high-grade DCIS, supporting the hypothesis that invasive carcinomas derive from the progression of preexisting DCIS [4, 10, 11]. The first step might be the abnormal response to growth factors, for example, mediated by estrogen receptors, which let the benign cells lose their ability to respond to normal apoptosis signals. Then, there would be the loss of function of some oncosuppressor genes as p53, the acquisition of some genetic instability with the loss of heterozygosity, and the onset of abnormal oncogenes such as HER2/neu. Finally, also changes in the surrounding stroma and neoangiogenesis occur, so that the preinvasive lesion becomes capable of invading the surrounding tissues for an imbalance between the gain of function by malignant cells and loss of function by the surrounding normal cells.

Many of the typical molecular characteristics of invasive lesions are already present in DCIS, such as genetic mutations, oncogenic expression, and loss of normal cell cycle regulation ability. The expression of molecular markers seems to have many points in common between in situ and invasive ductal carcinoma, supporting again the evolution of invasive carcinoma from DCIS. In the following section, these markers are discussed.

#### **2.2. Biomolecular markers**

**2. Histopathological aspects**

172 Cancer Management and Therapy

most cases the appearance is composite.

protrusions.

**2.1. Natural history**

The breast gland contains a ductal system that, with successive branches, ends distally in the terminal ductal-lobular units. Ducts and lobules are coated with two types of cells: luminal epithelial cells and myoepithelial cells. The myoepithelial cells contain myofilaments, have contractile capacity, and form a network structure located on the basal membrane. Histologically, the retention of the myoepithelial cell layer helps to distinguish in situ forms from invasive ones. DCIS is a neoplastic breast lesion, characterized by the presence in the ductal-lobular terminal unit of a malignant epithelial cell clone that does not exceed the basal membrane. DCIS includes a spectrum of different lesions from the histological point of view, with different architecture,

nuclear morphology, degree, and the eventual presence of necrosis and calcifications.

DCIS has been historically divided into five histological subtypes, based on the tumor cell growth modality: comedogenic, solid, cribriform, papillary, and micropapillary; however, in

Comedogenic DCIS is characterized by a solid proliferation of large pleomorphic cells, with abundant eosinophilic cytoplasm and high-grade hyperchromatic nuclei. A peculiar aspect of this DCIS is the presence of central necrosis which may give place to dystrophic calcifications, which are usually detected by mammography as clustered microcalcifications. Frequently, these lesions contain periductal fibrosis, due to the fibroblast response in the surrounding stroma, and a chronic inflammation component which may sometimes make these lesions clinically palpable. Noncomedogenic DCIS consists of a population of smaller and monomorphic neoplastic cells, with variable nuclear grading. Necrosis is minimal or absent and the periductal fibrosis is unfrequent. In the cribriform subtype, neoformed glandular spaces are uniformly distributed and have a regular shape. In the solid DCIS, neoplastic cells completely fill in the interested tissue. The papillary subtype grows, giving rise to papillary formations with the fibrovascular axis missing in the micropapillary DCIS, also characterized by interstitial papillary

The importance of this morphological classification has been downsized in recent years since this distinction does not take into account important prognostic factors such as nuclear grading, necrosis, and architecture [1, 2]. However, a distinction between comedogenic and noncomedogenic DCIS remains very significant, because of the poorer prognosis of the comedogenic type, which is at higher risk of evolution toward invasive carcinoma and of local recurrence [3].

Several classifications were subsequently proposed [1], taking into consideration nuclear grading, presence of necrosis, histological architecture and pattern, lesion size, number of involved ducts, cell polarization, and positivity for some receptors. The most used classifica-

Several recent studies have shown that invasive breast cancer results from a progression of in situ cancer that proliferates and increases to overcome the basal membrane of the ductal epithelium, thus becoming infiltrating. However, the probability that all invasive carcinomas

tion systems are those endowed with prognostic power.

The estrogen receptor is expressed in about 60% of DCIS [1] especially in those that exhibit less aggressive histological features such as low grading of differentiation and necrosis. The progesterone receptor expression seems to be consensual to that of the estrogen receptor.

HER2/neu is a member of the epidermal growth factor receptor (EGFR) family and is routinely studied in invasive carcinomas. It seems to be expressed by more than 40% of DCIS, especially by high-grade or comedogenic ones [12], so it would appear to be expressed in these lesions with a much higher frequency than that of invasive forms.

The expression of markers differs according to the nuclear grading of DCIS. In fact, considering only low-grade DCIS, some studies showed that in over 90% of cases it expresses the estrogen receptor, while in less than 20% of cases, it overexpresses HER2/neu or presents p53 mutations. In contrast, HER2/neu overexpression and p53 mutations are found in two thirds of high-grade DCIS, which expresses the estrogen receptor in only the 25% of cases.

of suspicious microcalcifications, the morphological aspect stability is not enough to exclude malignancy [26]. In this study, 25% of patients with malignancy finding at biopsy had microcalcifications with a stable appearance for 8–63 months. It is thus evident that morphology and distribution of microcalcifications are much more relevant in the decision-making pro-

Breast and Axilla Treatment in Ductal Carcinoma In Situ http://dx.doi.org/10.5772/intechopen.74340 175

Several studies attempted to correlate the appearance of microcalcifications and other DCIS mammographic findings with the biology of these lesions [13, 20, 21, 26–34]. The layout of calcifications reflects the localization of DCIS in the ductal system. Calcifications in a subareolar major duct may appear as a bundle of calcifications oriented toward the nipple. Calcifications in smaller ducts may have a branched appearance that reflects the extralobular endpoints, where most of the carcinomas originate. A branched radial pattern of calcifications means that

In several studies, most DCIS presented with granular microcalcifications [20, 27–31], but a radio-pathological correlation study showed that the histological type of DCIS cannot be accurately determined on the basis of the morphological aspect of microcalcifications found in mammography [31]. However, in this study, almost 80% of linear microcalcifications were associated with the comedogenic subtype, while granular microcalcifications were associated with noncomedogenic DCIS subtypes in more than half cases [31]. Fine pleomorphic or linear-branching calcifications were significantly associated with high-grade DCIS and necrosis [25, 31], whereas round calcifications were significantly associated with low-grade DCIS [25]. Similarly, other mammographic studies showed that linear calcifications are most frequently expression of high-grade DCIS, while fine granular ones are more typical of well-differentiated DCIS [32–35].

Although microcalcifications are the most frequent mammographic finding in the diagnosis of DCIS, this may assume less commonly other radiological aspects. Various studies in the literature report more than 10% of DCIS presenting with solid mass aspect, usually with welldefined margins [20, 21, 25]. This percentage rises if narrowing the survey to low-grade DCIS [17]. A mass-like aspect of DCIS may be the direct manifestation of a soft tissue mass or may be the result of periductal fibrosis, causing in this latter case an irregular or a bulging aspect

Further mammographic manifestations include architectural distortion and focal asymmetries. Architectural distortion may also be determined by the sclerosis of the interstitial tissue surrounding the DCIS [21] or the tumor invasion of Cooper's ligament [37]. Many low-grade DCIS appear to be mammographic masses or asymmetries [25] and, as a result, appear more frequently to be noncalcific lesions [34, 36]. Finally, Tabar et al. reported that the survival of women with masses or linear and linear-branching calcifications is considerably worse than

The use of magnetic resonance imaging (MRI) in the diagnosis of DCIS remains still an argument of great debate. The interest in using this tool for DCIS has grown following the brilliant results of its use in the invasive carcinoma. Initially, due to the different appearance of the two pathologies, this instrument was not considered adequate alone for the study of in situ

cess of clinicians.

of the mass [36].

intralobular endpoints are involved [21].

women with other types of microcalcifications [38].

**3.2. Magnetic resonance imaging**

#### **2.3. Multifocal and multicentric disease**

For its ability to spread within the ductal system, DCIS frequently presents with multiple outbreaks within the same quadrant (multifocality) or in different quadrants (multicentricity). Multifocality occurs in two thirds of patients with low- or intermediate-grade DCIS, characterized by a discontinuous growth. On the other hand, high-grade lesions tend to be continuous, with neoplastic cell outbreaks usually not farer than 5 mm [4, 13, 14]. Other reports, albeit with lower incidence, show a higher frequency of multifocality and multicentricity in DCIS, and many authors highlighted how mammography is less sensitive than magnetic resonance imaging in such cases and underestimates the extent of the disease [4, 15].

In a very old study, Lagios and colleagues found that the incidence of multicentricity increases with the lesion size [16]. In addition, DCIS can spread through the ducts within the ductal system to reach the nipple, without ever overcoming the basal membrane. This mode of growth characterizes Paget's disease of the nipple, a rare manifestation of breast cancer that occurs with crusty and pruriginous nipple erythema.

## **3. Diagnosis and imaging**

In the past, DCIS was clinically identified by objective examination by the presence of nipple discharge, Paget's disease, or a palpable mass. Today, clinical finding is rare, and DCIS is mostly identified by mammography or magnetic resonance imaging.

### **3.1. Mammography**

The sensitivity of mammography in detecting DCIS varies in the literature between 87 and 95% [17–19]. In a comparative study of mammographic and anatomopathological findings, the number of high-grade lesions not detected in mammography was significantly low [18]. Microcalcifications are the expression of cellular debris and calcified secretions within the intraductal lumen; can be extremely variable in size, shape, and appearance; and account for about 60–75% of all mammographic abnormalities in case of DCIS [20–25].

The diagnostic approach to breast microcalcifications is the analysis of morphology, distribution, and eventual modifications over time. According to the terminology of BI-RADS, the morphology can be classified as "pleomorphic," "linear," "branched linear," "amorphous," or "indistinct." The distribution of calcifications can be widespread or scattered throughout the breast, regional or distributed within a large volume of breast tissue (>2 cc), clustered if there are at least five calcifications in a small breast volume, segmental in the case where calcific deposits lie in ducts or branches of a lobe or breast segment.

Considering the changes in microcalcifications over time, in the presence of doubtful but probably benign mammographic findings, the absence of modifications after a certain period of time is reassuring. On the other hand, as underlined in a retrospective study, in the case of suspicious microcalcifications, the morphological aspect stability is not enough to exclude malignancy [26]. In this study, 25% of patients with malignancy finding at biopsy had microcalcifications with a stable appearance for 8–63 months. It is thus evident that morphology and distribution of microcalcifications are much more relevant in the decision-making process of clinicians.

Several studies attempted to correlate the appearance of microcalcifications and other DCIS mammographic findings with the biology of these lesions [13, 20, 21, 26–34]. The layout of calcifications reflects the localization of DCIS in the ductal system. Calcifications in a subareolar major duct may appear as a bundle of calcifications oriented toward the nipple. Calcifications in smaller ducts may have a branched appearance that reflects the extralobular endpoints, where most of the carcinomas originate. A branched radial pattern of calcifications means that intralobular endpoints are involved [21].

In several studies, most DCIS presented with granular microcalcifications [20, 27–31], but a radio-pathological correlation study showed that the histological type of DCIS cannot be accurately determined on the basis of the morphological aspect of microcalcifications found in mammography [31]. However, in this study, almost 80% of linear microcalcifications were associated with the comedogenic subtype, while granular microcalcifications were associated with noncomedogenic DCIS subtypes in more than half cases [31]. Fine pleomorphic or linear-branching calcifications were significantly associated with high-grade DCIS and necrosis [25, 31], whereas round calcifications were significantly associated with low-grade DCIS [25]. Similarly, other mammographic studies showed that linear calcifications are most frequently expression of high-grade DCIS, while fine granular ones are more typical of well-differentiated DCIS [32–35].

Although microcalcifications are the most frequent mammographic finding in the diagnosis of DCIS, this may assume less commonly other radiological aspects. Various studies in the literature report more than 10% of DCIS presenting with solid mass aspect, usually with welldefined margins [20, 21, 25]. This percentage rises if narrowing the survey to low-grade DCIS [17]. A mass-like aspect of DCIS may be the direct manifestation of a soft tissue mass or may be the result of periductal fibrosis, causing in this latter case an irregular or a bulging aspect of the mass [36].

Further mammographic manifestations include architectural distortion and focal asymmetries. Architectural distortion may also be determined by the sclerosis of the interstitial tissue surrounding the DCIS [21] or the tumor invasion of Cooper's ligament [37]. Many low-grade DCIS appear to be mammographic masses or asymmetries [25] and, as a result, appear more frequently to be noncalcific lesions [34, 36]. Finally, Tabar et al. reported that the survival of women with masses or linear and linear-branching calcifications is considerably worse than women with other types of microcalcifications [38].

#### **3.2. Magnetic resonance imaging**

mutations. In contrast, HER2/neu overexpression and p53 mutations are found in two thirds

For its ability to spread within the ductal system, DCIS frequently presents with multiple outbreaks within the same quadrant (multifocality) or in different quadrants (multicentricity). Multifocality occurs in two thirds of patients with low- or intermediate-grade DCIS, characterized by a discontinuous growth. On the other hand, high-grade lesions tend to be continuous, with neoplastic cell outbreaks usually not farer than 5 mm [4, 13, 14]. Other reports, albeit with lower incidence, show a higher frequency of multifocality and multicentricity in DCIS, and many authors highlighted how mammography is less sensitive than magnetic resonance

In a very old study, Lagios and colleagues found that the incidence of multicentricity increases with the lesion size [16]. In addition, DCIS can spread through the ducts within the ductal system to reach the nipple, without ever overcoming the basal membrane. This mode of growth characterizes Paget's disease of the nipple, a rare manifestation of breast cancer that occurs

In the past, DCIS was clinically identified by objective examination by the presence of nipple discharge, Paget's disease, or a palpable mass. Today, clinical finding is rare, and DCIS is

The sensitivity of mammography in detecting DCIS varies in the literature between 87 and 95% [17–19]. In a comparative study of mammographic and anatomopathological findings, the number of high-grade lesions not detected in mammography was significantly low [18]. Microcalcifications are the expression of cellular debris and calcified secretions within the intraductal lumen; can be extremely variable in size, shape, and appearance; and account for

The diagnostic approach to breast microcalcifications is the analysis of morphology, distribution, and eventual modifications over time. According to the terminology of BI-RADS, the morphology can be classified as "pleomorphic," "linear," "branched linear," "amorphous," or "indistinct." The distribution of calcifications can be widespread or scattered throughout the breast, regional or distributed within a large volume of breast tissue (>2 cc), clustered if there are at least five calcifications in a small breast volume, segmental in the case where cal-

Considering the changes in microcalcifications over time, in the presence of doubtful but probably benign mammographic findings, the absence of modifications after a certain period of time is reassuring. On the other hand, as underlined in a retrospective study, in the case

of high-grade DCIS, which expresses the estrogen receptor in only the 25% of cases.

imaging in such cases and underestimates the extent of the disease [4, 15].

mostly identified by mammography or magnetic resonance imaging.

about 60–75% of all mammographic abnormalities in case of DCIS [20–25].

cific deposits lie in ducts or branches of a lobe or breast segment.

**2.3. Multifocal and multicentric disease**

174 Cancer Management and Therapy

with crusty and pruriginous nipple erythema.

**3. Diagnosis and imaging**

**3.1. Mammography**

The use of magnetic resonance imaging (MRI) in the diagnosis of DCIS remains still an argument of great debate. The interest in using this tool for DCIS has grown following the brilliant results of its use in the invasive carcinoma. Initially, due to the different appearance of the two pathologies, this instrument was not considered adequate alone for the study of in situ lesions. A fundamental factor which led MRI to become an important tool in the preoperative diagnosis and evaluation of DCIS was the transition from high time resolution to high spatial resolution [39]. Another important factor is that MRI was used to study patients who had already been diagnosed with cancer by mammography, and only when MRI began to be used as a tool for screening on high-risk patients allowed more data to be compared about the accuracy of the two different diagnostic tools.

common internal enhancement pattern is the clumped one (51.5%), followed by the heteroge-

Breast and Axilla Treatment in Ductal Carcinoma In Situ http://dx.doi.org/10.5772/intechopen.74340 177

Evaluation of kinetics in DCIS is less significant compared to invasive lesions, and in fact the extent of perfusion increases with the progression of lesions from benign to in situ and even more invasive lesions [47]. Based on the BI-RADS classification, the kinetic aspect of DCIS has been standardized, and two phases of the enhancement can be recognized: an initial phase, within the first 2 minutes after administration of the contrast medium, and a delayed phase after 2 minutes. The initial phase can be rapid, intermediate, or slow; the delayed phase can be classified as persistent (the signal continues to increase), plateau (the signal density does not change after the initial increase), or washout (the signal decreases after the initial climb). DCIS is usually characterized by the fast initial phase and a washout in the delayed phase [24, 50]. Moreover, there is no statistically significant difference in the kinetic characteristics between

Despite the superiority of MRI in terms of sensitivity, its role in the management of in situ disease remains still controversial. According to recent studies, the routine use of MRI in DCIS does not change the clinical management in 99% of patients and lead to more unnecessary reexamination and longer time interval before surgery [52]. In a recent meta-analysis, the proportion of patients who changed the treatment based on MRI findings results about 15% [53]. Available evidence suggests that the percentage of patients with noninvasive cancer who may benefit from a preoperative MRI assessment is not very high and should be weighed with the economic availability and the delay in definitive treatment resulting from the increase in

Patients undergoing MRI do not show a significant reduction in the re-intervention rate for positive margins after conservative surgery [53]. Several studies also show that the routine use of preoperative MRI is associated with a greater incidence of mastectomy for invasive carcinoma and the trend seems to be the same for DCIS [43, 53–56]. On the contrary, conservative surgery rates are higher among women who do not undergo preoperative MRI [53], and this probably reflects the MRI ability to detect multifocal and multicentric disease and results in a greater number of women who are not candidates

The identification of a subgroup of patients with DCIS that could benefit from preoperative MRI needs further studies on DCIS biology, in particular on its potential to progress and recur. In fact, as outlined in the literature, only 30–50% of cases of DCIS evolve to invasive disease if untreated [57, 58], and consequently many patients who undergo mastectomy for DCIS would receive an overtreatment; whether preoperative MRI results an advantage in terms of

However, many agree that there is definitely an improvement of surgical outcomes [52–54, 59], and a study on DCIS and early invasive breast cancer does not reveal, after 4.6 years of median follow-up, significant differences in terms of recurrence, metastasis occurrence, mortality, or contralateral lesions rate between patients undergoing or not preoperative MRI [60]. The use of MRI in addition to mammography could help in defining the exact extension of

local control of disease and survival in patients with DCIS is still unclear.

DCIS, although MRI often overestimates the size of the primitive tumor [59].

neous (21%) and homogeneous ones (15%) [41].

DCIS of different grading [24, 51].

preoperative investigations.

for conservative surgery.

Several studies have been conducted to find out the multiple manifestations of DCIS by MRI and to correlate these with the biological characteristics of the disease. The superiority of MRI in the diagnosis of DCIS has been demonstrated in numerous studies with sensitivity ranging from 86 to 92% [15, 40–43]. MRI sensitivity is higher for high-grade lesions, regardless of whether or not there is necrosis, which instead affects the sensitivity of mammography in identifying high-grade DCIS [41, 42, 44, 45]. The pattern of breast lesion enhancement correlates with the biological profile of DCIS [46], because the diagnosis is based on tissue enhancement after administration of a contrast medium and to the hyperdensity of neoplastic lesions due to vascular permeability [47].

Angiogenesis in DCIS may be partly due to the destruction of the cellular myoepithelial cell surrounding the ducts [48]. Myoepithelial cells tend to be more preserved in low-grade DCIS while being lost or significantly absent in high-grade DCIS or with comedic necrosis. Recent studies also show that focal damage to the myoepithelial layer could trigger tumor invasion. The tumor cells adjacent to the point of damage tend to be more frequently associated with genetic and phenotypic alterations, such as loss of estrogen receptors, reduced expression of oncosuppressors, and increased expression of genes related to the cell cycle, angiogenesis, and invasive capacity [49].

The terminology of BI-RADS includes three types of responses to breast MRI: "mass-like enhancement" defined as a three-dimensional injury occupying a generally rounded area of oval or irregular shape, "focal enhancement" defined as a small enhancement spot <5 mm that does not allow a further morphological description, and "non-mass-like enhancement" described as enhancement of an area without forming a mass. This last manifestation is most common in DCIS, present in 60–80% of cases [15, 24, 39, 41], while invasive or mixed ductal lesions appear in over 75% of cases as "mass-like enhancement" [41].

Non-mass-like enhancement lesions are distinguished on the basis of the distribution pattern as segmental, linear, ductal, focal, regional, multiregional, and diffuse. Segmental means a triangular enhancement area with the apex toward the nipple suggesting the distribution of a duct and its branches. Linear is defined as an enhancement area that may not correspond to a duct, while ductal indicates a linear enhancement zone with ramifications like a duct. The regional pattern has a large volume of enhancement that cannot be assimilated to a duct, and the focal enhancement is confined to a smaller area than 25% of a quadrant. The segmental distribution is the most common non-mass-like DCIS presentation [15, 24, 41].

On the basis of the internal enhancement pattern, non-mass-like enhancement lesions are distinguished also as clumped, heterogeneous, and homogeneous. The internal enhancement pattern can be clumped if it takes a cobbled appearance with occasional confluence areas. It may be homogeneous or otherwise heterogeneous when it is or not uniform. The most common internal enhancement pattern is the clumped one (51.5%), followed by the heterogeneous (21%) and homogeneous ones (15%) [41].

lesions. A fundamental factor which led MRI to become an important tool in the preoperative diagnosis and evaluation of DCIS was the transition from high time resolution to high spatial resolution [39]. Another important factor is that MRI was used to study patients who had already been diagnosed with cancer by mammography, and only when MRI began to be used as a tool for screening on high-risk patients allowed more data to be compared about the

Several studies have been conducted to find out the multiple manifestations of DCIS by MRI and to correlate these with the biological characteristics of the disease. The superiority of MRI in the diagnosis of DCIS has been demonstrated in numerous studies with sensitivity ranging from 86 to 92% [15, 40–43]. MRI sensitivity is higher for high-grade lesions, regardless of whether or not there is necrosis, which instead affects the sensitivity of mammography in identifying high-grade DCIS [41, 42, 44, 45]. The pattern of breast lesion enhancement correlates with the biological profile of DCIS [46], because the diagnosis is based on tissue enhancement after administration of a contrast medium and to the hyperdensity of neoplastic lesions

Angiogenesis in DCIS may be partly due to the destruction of the cellular myoepithelial cell surrounding the ducts [48]. Myoepithelial cells tend to be more preserved in low-grade DCIS while being lost or significantly absent in high-grade DCIS or with comedic necrosis. Recent studies also show that focal damage to the myoepithelial layer could trigger tumor invasion. The tumor cells adjacent to the point of damage tend to be more frequently associated with genetic and phenotypic alterations, such as loss of estrogen receptors, reduced expression of oncosuppressors, and increased expression of genes related to the cell cycle, angiogenesis,

The terminology of BI-RADS includes three types of responses to breast MRI: "mass-like enhancement" defined as a three-dimensional injury occupying a generally rounded area of oval or irregular shape, "focal enhancement" defined as a small enhancement spot <5 mm that does not allow a further morphological description, and "non-mass-like enhancement" described as enhancement of an area without forming a mass. This last manifestation is most common in DCIS, present in 60–80% of cases [15, 24, 39, 41], while invasive or mixed ductal

Non-mass-like enhancement lesions are distinguished on the basis of the distribution pattern as segmental, linear, ductal, focal, regional, multiregional, and diffuse. Segmental means a triangular enhancement area with the apex toward the nipple suggesting the distribution of a duct and its branches. Linear is defined as an enhancement area that may not correspond to a duct, while ductal indicates a linear enhancement zone with ramifications like a duct. The regional pattern has a large volume of enhancement that cannot be assimilated to a duct, and the focal enhancement is confined to a smaller area than 25% of a quadrant. The segmental

On the basis of the internal enhancement pattern, non-mass-like enhancement lesions are distinguished also as clumped, heterogeneous, and homogeneous. The internal enhancement pattern can be clumped if it takes a cobbled appearance with occasional confluence areas. It may be homogeneous or otherwise heterogeneous when it is or not uniform. The most

lesions appear in over 75% of cases as "mass-like enhancement" [41].

distribution is the most common non-mass-like DCIS presentation [15, 24, 41].

accuracy of the two different diagnostic tools.

due to vascular permeability [47].

176 Cancer Management and Therapy

and invasive capacity [49].

Evaluation of kinetics in DCIS is less significant compared to invasive lesions, and in fact the extent of perfusion increases with the progression of lesions from benign to in situ and even more invasive lesions [47]. Based on the BI-RADS classification, the kinetic aspect of DCIS has been standardized, and two phases of the enhancement can be recognized: an initial phase, within the first 2 minutes after administration of the contrast medium, and a delayed phase after 2 minutes. The initial phase can be rapid, intermediate, or slow; the delayed phase can be classified as persistent (the signal continues to increase), plateau (the signal density does not change after the initial increase), or washout (the signal decreases after the initial climb). DCIS is usually characterized by the fast initial phase and a washout in the delayed phase [24, 50]. Moreover, there is no statistically significant difference in the kinetic characteristics between DCIS of different grading [24, 51].

Despite the superiority of MRI in terms of sensitivity, its role in the management of in situ disease remains still controversial. According to recent studies, the routine use of MRI in DCIS does not change the clinical management in 99% of patients and lead to more unnecessary reexamination and longer time interval before surgery [52]. In a recent meta-analysis, the proportion of patients who changed the treatment based on MRI findings results about 15% [53]. Available evidence suggests that the percentage of patients with noninvasive cancer who may benefit from a preoperative MRI assessment is not very high and should be weighed with the economic availability and the delay in definitive treatment resulting from the increase in preoperative investigations.

Patients undergoing MRI do not show a significant reduction in the re-intervention rate for positive margins after conservative surgery [53]. Several studies also show that the routine use of preoperative MRI is associated with a greater incidence of mastectomy for invasive carcinoma and the trend seems to be the same for DCIS [43, 53–56]. On the contrary, conservative surgery rates are higher among women who do not undergo preoperative MRI [53], and this probably reflects the MRI ability to detect multifocal and multicentric disease and results in a greater number of women who are not candidates for conservative surgery.

The identification of a subgroup of patients with DCIS that could benefit from preoperative MRI needs further studies on DCIS biology, in particular on its potential to progress and recur. In fact, as outlined in the literature, only 30–50% of cases of DCIS evolve to invasive disease if untreated [57, 58], and consequently many patients who undergo mastectomy for DCIS would receive an overtreatment; whether preoperative MRI results an advantage in terms of local control of disease and survival in patients with DCIS is still unclear.

However, many agree that there is definitely an improvement of surgical outcomes [52–54, 59], and a study on DCIS and early invasive breast cancer does not reveal, after 4.6 years of median follow-up, significant differences in terms of recurrence, metastasis occurrence, mortality, or contralateral lesions rate between patients undergoing or not preoperative MRI [60]. The use of MRI in addition to mammography could help in defining the exact extension of DCIS, although MRI often overestimates the size of the primitive tumor [59].

#### **3.3. Screening**

Mammography is considered to be the most effective screening test for the detection of early breast cancer. In Italy, biennial mammography is recommended in women aged between 50 and 69 [61, 62]. In women aged between 40 and 49, it should be performed only based on the familiar history, individual risk, and breast density, possibly accompanied by an ultrasound examination. In women aged over 70, there is no evidence of the effectiveness of mammographic screening, but the possibility of extending it to 75 years is considered. The relative reduction in mortality for breast cancer is 14% in women aged between 50 and 59 and 32% in the 60–69 range, reflecting the direct correlation of mammography sensitivity with age, related to the reduction in breast density [63].

The main objection to the screen detection of DCIS comes from the observation that misdiagnosed DCIS is much less likely than invasive tumors to become clinically evident [66]. In fact, it is evident that there are breast cancers that will never become lethal and that many women receive systemic therapies without knowing who will benefit from it, but the risk of overdiagnosis is lower than the benefits [70]. From a clinical point of view, the best and most prudent way to deal with DCIS is to consider it as a potential future invasive carcinoma [71].

Breast and Axilla Treatment in Ductal Carcinoma In Situ http://dx.doi.org/10.5772/intechopen.74340 179

The uncertainty about the natural history of DCIS and the impossibility to determine predictive factors for which lesions will progress to invasive forms make the therapeutic choice extremely difficult. Initially, standard therapy was the simple mastectomy in 98–99% of patients [77]. Subsequently, with the introduction of always more conservative treatments for invasive carcinomas, the breast-conserving surgery (BCS) became progressively the most frequently used surgery for DCIS. There are, however, no randomized studies comparing

The currently recommended therapeutic options of the National Comprehensive Cancer Network (NCCN) include mastectomy and lumpectomy with or without radiotherapy and with the possible addition of tamoxifen in the case of hormone-positive DCIS. Randomized trials indicate that lumpectomy associated with radiotherapy results in the lowest recurrence

According to a recent article by Worni and colleagues, among 121,080 women with DCIS diagnosed from 1991 to 2010, most patients received radiotherapy (43%) after lumpectomy, followed by lumpectomy alone (26.5%), unilateral mastectomy (23.8%), bilateral mastectomy (4.5%), and ultimately no treatment (2.3%) [78]. In the 20 years of study, trends in the treatment choice have changed, with a considerable increase in lumpectomy with radiotherapy (100% increase). Also, the significant increase in the number of bilateral mastectomies, a trend that seems to be driven more by the choice of bilateral prophylactic mastectomy than by the

Breast-conserving surgery (BCS) in the treatment of invasive breast cancer has gone affirming over the years, thanks to studies that demonstrated no significant difference in survival rates compared to mastectomy. However, this evidence has not yet been reached in the case of DCIS, and to date there are no randomized comparisons of mastectomy and BCS in women with DCIS. However, retrospective studies did not show any difference in the overall and

Several studies have been conducted in the attempt to determine the magnitude of the recurrence risk in patients with DCIS, in order to use this information to improve the therapeutic approach, but there are no definitive results on the effectiveness of BCS without radiotherapy,

which, according to Worni et al., is still used today in about a quarter of cases [78].

rate but does not show any difference in overall and disease-free survival [78].

**4. Surgical treatment**

outcomes after mastectomy and BCS [12, 64].

need to treat bilateral disease, is interesting.

disease-free survival between the two strategies [79, 80].

**4.1. Conservative breast surgery**

MRI is not recommended as a screening survey in the general population [64] due to its low specificity and hence its higher number of false positives. The use of MRI as a screening method, in addition to mammography and clinical examination, is justified in high- and moderate-risk women, who include women with BRCA1 or BRCA2 mutations; previous chest wall radiotherapy between 10 and 30 years of age; Li-Fraumeni, Cowden, or Bannayan-Riley-Ruvalcaba syndrome; personal history of DCIS; atypical ductal hyperplasia; and lobular intraepithelial neoplasia.

Tomosynthesis, which combines conventional, two-dimensional images with three-dimensional, multilayer images, appears to be particularly effective in case of dense breasts, where the volumetric overlap of traditional mammography images prevents some lesions from being identified. In a study of 9672 women, the combination of mammography and tomosynthesis increased not only the cancer detection rate but also the number of false positives [65].

The incidence of screen-detected DCIS varies between 15 and 30% [66–70]. It is greater in women aged between 40 and 49 (28.2%) than in older women (16–20.5%). The age-adjusted incidence rate increased from 2.4 to 27.7 per 100,000 women between 1981 and 2001 [36]. In line with these data, some studies reported an estimated annual DCIS incidence of 32.5 per 100,000 women [71]. The overall screen-detected DCIS rate results 0.78 per 1000 mammograms, indicating that one DCIS is approximately identified every 1300 screening mammograms [66].

The mammographic screening resulted in a mortality reduction of about 20–30% [72–74], but screening value remains uncertain in the case of DCIS. Some authors argue that it prevents the incidence of a large number of invasive tumors and contributes substantially to survival improvement. Others claim that this type of injury does not always progress to invasive cancer and in those cases it would not lead to death, and indeed, its response to screening would be a source of overdiagnosis, resulting in more harm than good [75]. The epidemiological definition of overdiagnosis is the difference between observed and expected incidences [70].

A study estimated that, of the 141 screened deaths, 17 were determined by the progression of DCIS to invasive carcinoma and therefore concluded that the detection of DCIS at screening prevented 12% of the overall avoided deaths with screening [75]. Another interesting evidence is that the majority of screen-detected DCIS are of high-grade and have a more pronounced tendency to present necrosis, suggesting that screen-detected lesions have a higher risk of progression [76].

The main objection to the screen detection of DCIS comes from the observation that misdiagnosed DCIS is much less likely than invasive tumors to become clinically evident [66]. In fact, it is evident that there are breast cancers that will never become lethal and that many women receive systemic therapies without knowing who will benefit from it, but the risk of overdiagnosis is lower than the benefits [70]. From a clinical point of view, the best and most prudent way to deal with DCIS is to consider it as a potential future invasive carcinoma [71].

## **4. Surgical treatment**

**3.3. Screening**

178 Cancer Management and Therapy

related to the reduction in breast density [63].

lar intraepithelial neoplasia.

risk of progression [76].

Mammography is considered to be the most effective screening test for the detection of early breast cancer. In Italy, biennial mammography is recommended in women aged between 50 and 69 [61, 62]. In women aged between 40 and 49, it should be performed only based on the familiar history, individual risk, and breast density, possibly accompanied by an ultrasound examination. In women aged over 70, there is no evidence of the effectiveness of mammographic screening, but the possibility of extending it to 75 years is considered. The relative reduction in mortality for breast cancer is 14% in women aged between 50 and 59 and 32% in the 60–69 range, reflecting the direct correlation of mammography sensitivity with age,

MRI is not recommended as a screening survey in the general population [64] due to its low specificity and hence its higher number of false positives. The use of MRI as a screening method, in addition to mammography and clinical examination, is justified in high- and moderate-risk women, who include women with BRCA1 or BRCA2 mutations; previous chest wall radiotherapy between 10 and 30 years of age; Li-Fraumeni, Cowden, or Bannayan-Riley-Ruvalcaba syndrome; personal history of DCIS; atypical ductal hyperplasia; and lobu-

Tomosynthesis, which combines conventional, two-dimensional images with three-dimensional, multilayer images, appears to be particularly effective in case of dense breasts, where the volumetric overlap of traditional mammography images prevents some lesions from being identified. In a study of 9672 women, the combination of mammography and tomosynthesis increased not only the cancer detection rate but also the number of false positives [65]. The incidence of screen-detected DCIS varies between 15 and 30% [66–70]. It is greater in women aged between 40 and 49 (28.2%) than in older women (16–20.5%). The age-adjusted incidence rate increased from 2.4 to 27.7 per 100,000 women between 1981 and 2001 [36]. In line with these data, some studies reported an estimated annual DCIS incidence of 32.5 per 100,000 women [71]. The overall screen-detected DCIS rate results 0.78 per 1000 mammograms, indicating that one DCIS is approximately identified every 1300 screening mammograms [66].

The mammographic screening resulted in a mortality reduction of about 20–30% [72–74], but screening value remains uncertain in the case of DCIS. Some authors argue that it prevents the incidence of a large number of invasive tumors and contributes substantially to survival improvement. Others claim that this type of injury does not always progress to invasive cancer and in those cases it would not lead to death, and indeed, its response to screening would be a source of overdiagnosis, resulting in more harm than good [75]. The epidemiological definition of overdiagnosis is the difference between observed and expected incidences [70]. A study estimated that, of the 141 screened deaths, 17 were determined by the progression of DCIS to invasive carcinoma and therefore concluded that the detection of DCIS at screening prevented 12% of the overall avoided deaths with screening [75]. Another interesting evidence is that the majority of screen-detected DCIS are of high-grade and have a more pronounced tendency to present necrosis, suggesting that screen-detected lesions have a higher The uncertainty about the natural history of DCIS and the impossibility to determine predictive factors for which lesions will progress to invasive forms make the therapeutic choice extremely difficult. Initially, standard therapy was the simple mastectomy in 98–99% of patients [77]. Subsequently, with the introduction of always more conservative treatments for invasive carcinomas, the breast-conserving surgery (BCS) became progressively the most frequently used surgery for DCIS. There are, however, no randomized studies comparing outcomes after mastectomy and BCS [12, 64].

The currently recommended therapeutic options of the National Comprehensive Cancer Network (NCCN) include mastectomy and lumpectomy with or without radiotherapy and with the possible addition of tamoxifen in the case of hormone-positive DCIS. Randomized trials indicate that lumpectomy associated with radiotherapy results in the lowest recurrence rate but does not show any difference in overall and disease-free survival [78].

According to a recent article by Worni and colleagues, among 121,080 women with DCIS diagnosed from 1991 to 2010, most patients received radiotherapy (43%) after lumpectomy, followed by lumpectomy alone (26.5%), unilateral mastectomy (23.8%), bilateral mastectomy (4.5%), and ultimately no treatment (2.3%) [78]. In the 20 years of study, trends in the treatment choice have changed, with a considerable increase in lumpectomy with radiotherapy (100% increase). Also, the significant increase in the number of bilateral mastectomies, a trend that seems to be driven more by the choice of bilateral prophylactic mastectomy than by the need to treat bilateral disease, is interesting.

#### **4.1. Conservative breast surgery**

Breast-conserving surgery (BCS) in the treatment of invasive breast cancer has gone affirming over the years, thanks to studies that demonstrated no significant difference in survival rates compared to mastectomy. However, this evidence has not yet been reached in the case of DCIS, and to date there are no randomized comparisons of mastectomy and BCS in women with DCIS. However, retrospective studies did not show any difference in the overall and disease-free survival between the two strategies [79, 80].

Several studies have been conducted in the attempt to determine the magnitude of the recurrence risk in patients with DCIS, in order to use this information to improve the therapeutic approach, but there are no definitive results on the effectiveness of BCS without radiotherapy, which, according to Worni et al., is still used today in about a quarter of cases [78].

BCS consists in the excision of the lesion surrounded by about 1 centimeter of macroscopically health tissue. It may be a simple wide excision of breast parenchyma, also called lumpectomy, or a cylindrical excision of breast tissue including the overlying skin and the underlying muscle fascia, also known as quadrantectomy [81]. In case of nonpalpable breast lesions, many different techniques can be used in order to intraoperatively guide the surgical resection, such as the preoperative placement of a wire hook or a radioactive tracer [82].

aromatase inhibitors are considered, while no evidence supports the use of adjuvant chemo-

Breast and Axilla Treatment in Ductal Carcinoma In Situ http://dx.doi.org/10.5772/intechopen.74340 181

With the introduction of adjuvant radiotherapy after BCS for invasive breast carcinoma, the interest in radiotherapy application for DCIS has also greatly increased. A lot of studies in the literature evaluated the efficacy of this treatment in DCIS patients, and according to the current guidelines, radiotherapy after BCS results is strongly recommended in patients with DCIS [64].

Breast irradiation usually includes all the residual breast (whole breast irradiation), is classically performed within 6 months after surgery, and usually consists in 25 sessions, even if also shorter hypofractionated protocols are described. Anyway, radiation therapy may be also limited to the area surrounding the tumor (partial breast irradiation) and be performed intraoperatively immediately after the tumor excision, as happens for the intraoperative radio-

A recent meta-analysis of the Early Breast Cancer Trialists' Collaborative Group (EBCTCG) on individual data from four randomized studies showed that adjuvant radiotherapy reduces 15.2% of the absolute risk of 10-year ipsilateral invasive relapse after surgery for DCIS, anyway without any significant effect on survival [95]. These data confirm the findings of previous international randomized trials that generally showed a reduction by about 50–60% in ipsilateral breast recur-

Recurrences after BCS for DCIS are usually half invasive and half in situ. With the addition of radiotherapy to BCS, the annual invasive recurrence rate results about 0.5–1%. The possible benefits of this therapeutic choice on survival would be the reduction of invasive recurrences

According to recent reports, most patients are subjected to lumpectomy followed by radiotherapy, and this therapeutic option raised from the 25% of treatments in 1991 to the 50% in 2010 [78]. Patients who refuse radiotherapy after BCS should be properly informed of the potential for greater local recurrence risk, although a survival benefit may not yet be evidenced by studies due to the insufficient number of patients examined and to the very low

Given the important role of the estrogenic pathway in the pathogenesis of breast carcinomas, many strategies have been developed which can control estrogen-sensible tissues. The first experimented drug was tamoxifen, a selective estrogen receptor modulator (SERM), which has the ability to act as an estrogenic agonist in certain tissues such as bone and endometrium, while it acts as a powerful estrogenic antagonist in others including the breast. For these properties it is widely used in the treatment of invasive breast cancer, where it has been shown to

The role of adjuvant therapy with tamoxifen for DCIS was analyzed in two major randomized trials. The NSABP B-24 study randomized 1804 women with DCIS between BCS followed by

reduce the risk of relapse and death after surgical treatment [100].

rences in patients who received radiotherapy after BCS compared to BCS alone [96–99].

and the consequent reduction of mortality [77, 98].

mortality rate for this disease [71].

**5.2. Hormonal therapy**

therapy in the treatment of DCIS [64].

**5.1. Radiation therapy**

therapy (IORT) [94].

The specimen is then oriented with some stitched in order to facilitate the margin evaluation by the pathologist [83]. In particular, a negative margin greater than 2 mm represents nowadays the adequate margin for DCIS [84]. Moreover, in some cases also a cavity shaving may be performed, although there is no evidence that this procedure will significantly reduce reinterventions for margin positivity.

#### **4.2. Mastectomy**

Mastectomy consists in the complete mammary gland excision together with the overlying skin and the nipple-areola complex, as well as the underlying muscle fascia. Nowadays, even more conservative techniques have been developed, so that it is possible to spare the skin with or without the nipple-areola complex by performing the so-called nipple-sparing mastectomy or skin-sparing mastectomy [85–91].

For what concerns these two last procedures, there are still controversies about the long-term oncological results, as, for example, the nipple includes the terminal portion of the breast ducts and may then represent a place at risk of recurrence. However, the esthetic results are undiscussed, and these kinds of techniques result in an essential improvement in the psychophysical wellness of women undergoing breast demolition.

Mastectomy is a healing process in 98–99% of patients with DCIS. The relapses after this intervention may be in situ but also invasive and can occur both as a local recurrence and a distant metastasis [77]. After mastectomy, the reported recurrence rate is less than 1.5% in most studies [92, 93]. The use of skin-sparing mastectomy does not correlate with a significant increase in local recurrences [93].

Recurrence after mastectomy for DCIS could be due to the lack of sampling or recognition of an invasive component or incomplete removal of the involved breast tissue. However, the fact that the majority of recurrences after mastectomy occur in the first 5 years suggests that most of these are due to the lack of recognition of an invasive carcinoma rather than the malignant transformation of the residual breast tissue [77].

Finally, mastectomy is an effective treatment for DCIS, but its use should be carefully evaluated in the light of a pathology that does not present the risk of remote metastasis, typical of infiltrating forms, which will not necessarily become invasive.

## **5. Adjuvant treatments**

Although DCIS is a local disease, the use of both local and systemic adjuvant therapies is widespread. In particular, adjuvant radiotherapy after BCS and the use of tamoxifen or aromatase inhibitors are considered, while no evidence supports the use of adjuvant chemotherapy in the treatment of DCIS [64].

#### **5.1. Radiation therapy**

BCS consists in the excision of the lesion surrounded by about 1 centimeter of macroscopically health tissue. It may be a simple wide excision of breast parenchyma, also called lumpectomy, or a cylindrical excision of breast tissue including the overlying skin and the underlying muscle fascia, also known as quadrantectomy [81]. In case of nonpalpable breast lesions, many different techniques can be used in order to intraoperatively guide the surgical resection, such

The specimen is then oriented with some stitched in order to facilitate the margin evaluation by the pathologist [83]. In particular, a negative margin greater than 2 mm represents nowadays the adequate margin for DCIS [84]. Moreover, in some cases also a cavity shaving may be performed, although there is no evidence that this procedure will significantly reduce re-

Mastectomy consists in the complete mammary gland excision together with the overlying skin and the nipple-areola complex, as well as the underlying muscle fascia. Nowadays, even more conservative techniques have been developed, so that it is possible to spare the skin with or without the nipple-areola complex by performing the so-called nipple-sparing mastectomy

For what concerns these two last procedures, there are still controversies about the long-term oncological results, as, for example, the nipple includes the terminal portion of the breast ducts and may then represent a place at risk of recurrence. However, the esthetic results are undiscussed, and these kinds of techniques result in an essential improvement in the psycho-

Mastectomy is a healing process in 98–99% of patients with DCIS. The relapses after this intervention may be in situ but also invasive and can occur both as a local recurrence and a distant metastasis [77]. After mastectomy, the reported recurrence rate is less than 1.5% in most studies [92, 93]. The use of skin-sparing mastectomy does not correlate with a significant

Recurrence after mastectomy for DCIS could be due to the lack of sampling or recognition of an invasive component or incomplete removal of the involved breast tissue. However, the fact that the majority of recurrences after mastectomy occur in the first 5 years suggests that most of these are due to the lack of recognition of an invasive carcinoma rather than the malignant

Finally, mastectomy is an effective treatment for DCIS, but its use should be carefully evaluated in the light of a pathology that does not present the risk of remote metastasis, typical of

Although DCIS is a local disease, the use of both local and systemic adjuvant therapies is widespread. In particular, adjuvant radiotherapy after BCS and the use of tamoxifen or

as the preoperative placement of a wire hook or a radioactive tracer [82].

interventions for margin positivity.

or skin-sparing mastectomy [85–91].

increase in local recurrences [93].

**5. Adjuvant treatments**

transformation of the residual breast tissue [77].

infiltrating forms, which will not necessarily become invasive.

physical wellness of women undergoing breast demolition.

**4.2. Mastectomy**

180 Cancer Management and Therapy

With the introduction of adjuvant radiotherapy after BCS for invasive breast carcinoma, the interest in radiotherapy application for DCIS has also greatly increased. A lot of studies in the literature evaluated the efficacy of this treatment in DCIS patients, and according to the current guidelines, radiotherapy after BCS results is strongly recommended in patients with DCIS [64].

Breast irradiation usually includes all the residual breast (whole breast irradiation), is classically performed within 6 months after surgery, and usually consists in 25 sessions, even if also shorter hypofractionated protocols are described. Anyway, radiation therapy may be also limited to the area surrounding the tumor (partial breast irradiation) and be performed intraoperatively immediately after the tumor excision, as happens for the intraoperative radiotherapy (IORT) [94].

A recent meta-analysis of the Early Breast Cancer Trialists' Collaborative Group (EBCTCG) on individual data from four randomized studies showed that adjuvant radiotherapy reduces 15.2% of the absolute risk of 10-year ipsilateral invasive relapse after surgery for DCIS, anyway without any significant effect on survival [95]. These data confirm the findings of previous international randomized trials that generally showed a reduction by about 50–60% in ipsilateral breast recurrences in patients who received radiotherapy after BCS compared to BCS alone [96–99].

Recurrences after BCS for DCIS are usually half invasive and half in situ. With the addition of radiotherapy to BCS, the annual invasive recurrence rate results about 0.5–1%. The possible benefits of this therapeutic choice on survival would be the reduction of invasive recurrences and the consequent reduction of mortality [77, 98].

According to recent reports, most patients are subjected to lumpectomy followed by radiotherapy, and this therapeutic option raised from the 25% of treatments in 1991 to the 50% in 2010 [78]. Patients who refuse radiotherapy after BCS should be properly informed of the potential for greater local recurrence risk, although a survival benefit may not yet be evidenced by studies due to the insufficient number of patients examined and to the very low mortality rate for this disease [71].

#### **5.2. Hormonal therapy**

Given the important role of the estrogenic pathway in the pathogenesis of breast carcinomas, many strategies have been developed which can control estrogen-sensible tissues. The first experimented drug was tamoxifen, a selective estrogen receptor modulator (SERM), which has the ability to act as an estrogenic agonist in certain tissues such as bone and endometrium, while it acts as a powerful estrogenic antagonist in others including the breast. For these properties it is widely used in the treatment of invasive breast cancer, where it has been shown to reduce the risk of relapse and death after surgical treatment [100].

The role of adjuvant therapy with tamoxifen for DCIS was analyzed in two major randomized trials. The NSABP B-24 study randomized 1804 women with DCIS between BCS followed by radiotherapy and tamoxifen for 5 years versus BCS followed by radiotherapy and placebo for 5 years [101]. This study demonstrated a significant reduction of events after 5 years in the tamoxifen group compared to the placebo one. In particular, a reduction was observed in the risk of invasive relapse in both the ipsilateral and the contralateral breasts. However, for what concerns noninvasive relapses, the addition of tamoxifen was not proven to be significant.

the DCIS and the lack of effective medical therapies for DCIS which does not express estrogen receptors. These considerations have led to the development of two studies on the role of trastuzumab in DCIS. The first study, conducted by Gonzalez et al. with not yet conclusive results, evaluated the benefit of neoadjuvant trastuzumab in DCIS of less than 1 cm. The sec-

Breast and Axilla Treatment in Ductal Carcinoma In Situ http://dx.doi.org/10.5772/intechopen.74340 183

In agreement with the American Joint Committee on Cancer, microinvasive breast cancer is defined as a DCIS where the invasive component is microscopic and does not exceed the size of 1 mm [105]. In the current literature, microinvasive cancer prevalence accounts for about 10–20% of DCIS cases, and it does not represent more than 1% of all breast cancers

The natural history of these lesions is unclear; however, DCIS with microinvasion could be an intermediate stage in the invasive evolution. As a proof of this, the microinvasive carcinoma is often associated with DCIS, particularly large and with comedonecrosis [1, 64], and may be formed by small foci of tumor cells that, after crossing the basal membrane, infiltrate the surrounding stroma [64]. The age of presentation does not seem to be significantly different

Almost all DCIS with microinvasion are identified by the presence of microcalcifications at mammography [111]. Occasionally, the microinvasive carcinoma appears as a palpable mass with serum or blood vessel secretions from the nipple or as Paget's disease [112–114]. Microinvasive lesions tend to be larger in size and therefore more often palpable than purely in situ lesions. The detection of a microinvasion within a DCIS can be extremely difficult for the pathologist because of the many patterns with which the lesion can invade the stroma [77]. Usually, the microinvasion foci tend to be accompanied by a stromal response characterized by inflammatory cells scattered in one neoformed connective matrix [115]. Moreover, the use of immunohistochemical markers specific for the basal membrane or myoepithelial cells can

Concerning the therapeutic implications, data is not uniform. Surgical treatment can be both conservative and radical. According to recent reports, the use of mastectomy is significantly less frequent for this type of lesion than for invasive carcinomas, and the same happens for adjuvant therapies, generally reserved only for patients with triple-negative carcinomas, HER2-positive breast cancer, or with lymph node involvement [106]. The use of adjuvant radiotherapy is even higher in the group of microinvasive carcinoma than in that of invasive

According to the AIOM guidelines, mastectomy is indicated in these tumors in the presence of large intraductal component, particularly unfavorable histological characteristics (high-grade and comedonecrosis), or when it is not possible to obtain an adequate resection margin with a conservative resection [64]. BCS is also contraindicated after previous chest wall irradiation, during pregnancy, or in the case of multicentric lesions or diffused microcalcifications [110].

ond one, conducted from the NSBP, has not yet been completed.

**6. The microinvasive component**

from that of invasive or in situ forms [106].

help identify microinvasion in doubtful cases [115].

one, possibly due to the higher prevalence of conservative surgery.

[1, 106–110].

The benefit in women treated with tamoxifen was also significant after 163 months of followup [95], and over 15 years of follow-up, adjuvant tamoxifen reduced the risk of recurrence of ipsilateral breast cancer by 31% [99]. A retrospective analysis, conducted on 41% of the original study population, evaluated the relationship between estrogen receptor expression and tamoxifen benefit. It has been shown that treatment with tamoxifen significantly reduced the risk of subsequent breast cancer at 10 and 14.5 years, while in patients without expression of estrogen receptors, no benefit was observed. Finally, there were no differences in survival between the two arms of the NSABP B-24 trial.

The randomized phase II trial UK/ANZ DCIS93 evaluated the role of radiotherapy and tamoxifen in the treatment of patients undergoing BCS for DCIS, enrolling 1701 patients [102]. It analyzed the following therapeutic approaches: surgery alone, surgery followed by radiotherapy, surgery followed by tamoxifen for 5 years, and surgery followed by both radiotherapy and tamoxifen for 5 years. As for the use of tamoxifen, at 12 years of median follow-up, the study showed a reduction of ipsilateral in situ relapses, while there seemed to be no effect on the invasive ipsilateral recurrence.

Considering these two trials as a whole, it emerges that adjuvant tamoxifen, associated with radiotherapy, reduces the risk of in situ ipsilateral recurrences in the case of DCIS which expresses hormonal receptor, independently by the patient's age [48, 64]. Thereafter, the decision whether to propose tamoxifen as adjuvant treatment should be based on the evaluation of its side effects and potential benefits.

In postmenopausal women with invasive breast cancer, the aromatase inhibitors have been shown to be more effective than tamoxifen in reducing recurrences and preventing new contralateral cancers after surgery [100]. The second International Breast Cancer Intervention Study (IBIS-II) had the aim of studying the role of aromatase inhibitors in both primary prevention and adjuvant therapy in women with DCIS [102]. The NSABP B-35 study had similar objectives and compared tamoxifen with anastrozole for 5 years in 3000 postmenopausal women who underwent surgery and radiotherapy for DCIS, and, at a median follow-up of 8.6 years of treatment, anastrozole significantly improved the disease-free survival [103].

#### **5.3. Other medical therapies**

HER-2/neu is overexpressed in a variable number of DCIS [100] and appears to be related to an increase in local recurrences [104]. A retrospective analysis of 10,853 women enrolled in the EORTC trial showed that, of the 31 local relapses occurring in patients with DCIS, 24 were associated with in situ lesions that overexpressed HER-2/neu. The real meaning of HER-2/ neu overexpression in DCIS is currently the object of the study, given its importance as a prognostic and predictive factor in the invasive cancer. The use of trastuzumab, a monoclonal antibody targeting HER-2/neu, is interesting given the relative frequency of its presence in the DCIS and the lack of effective medical therapies for DCIS which does not express estrogen receptors. These considerations have led to the development of two studies on the role of trastuzumab in DCIS. The first study, conducted by Gonzalez et al. with not yet conclusive results, evaluated the benefit of neoadjuvant trastuzumab in DCIS of less than 1 cm. The second one, conducted from the NSBP, has not yet been completed.

## **6. The microinvasive component**

radiotherapy and tamoxifen for 5 years versus BCS followed by radiotherapy and placebo for 5 years [101]. This study demonstrated a significant reduction of events after 5 years in the tamoxifen group compared to the placebo one. In particular, a reduction was observed in the risk of invasive relapse in both the ipsilateral and the contralateral breasts. However, for what concerns noninvasive relapses, the addition of tamoxifen was not proven to be significant.

The benefit in women treated with tamoxifen was also significant after 163 months of followup [95], and over 15 years of follow-up, adjuvant tamoxifen reduced the risk of recurrence of ipsilateral breast cancer by 31% [99]. A retrospective analysis, conducted on 41% of the original study population, evaluated the relationship between estrogen receptor expression and tamoxifen benefit. It has been shown that treatment with tamoxifen significantly reduced the risk of subsequent breast cancer at 10 and 14.5 years, while in patients without expression of estrogen receptors, no benefit was observed. Finally, there were no differences in survival

The randomized phase II trial UK/ANZ DCIS93 evaluated the role of radiotherapy and tamoxifen in the treatment of patients undergoing BCS for DCIS, enrolling 1701 patients [102]. It analyzed the following therapeutic approaches: surgery alone, surgery followed by radiotherapy, surgery followed by tamoxifen for 5 years, and surgery followed by both radiotherapy and tamoxifen for 5 years. As for the use of tamoxifen, at 12 years of median follow-up, the study showed a reduction of ipsilateral in situ relapses, while there seemed to be no effect

Considering these two trials as a whole, it emerges that adjuvant tamoxifen, associated with radiotherapy, reduces the risk of in situ ipsilateral recurrences in the case of DCIS which expresses hormonal receptor, independently by the patient's age [48, 64]. Thereafter, the decision whether to propose tamoxifen as adjuvant treatment should be based on the evaluation

In postmenopausal women with invasive breast cancer, the aromatase inhibitors have been shown to be more effective than tamoxifen in reducing recurrences and preventing new contralateral cancers after surgery [100]. The second International Breast Cancer Intervention Study (IBIS-II) had the aim of studying the role of aromatase inhibitors in both primary prevention and adjuvant therapy in women with DCIS [102]. The NSABP B-35 study had similar objectives and compared tamoxifen with anastrozole for 5 years in 3000 postmenopausal women who underwent surgery and radiotherapy for DCIS, and, at a median follow-up of 8.6 years of treatment, anastrozole significantly improved the disease-free survival [103].

HER-2/neu is overexpressed in a variable number of DCIS [100] and appears to be related to an increase in local recurrences [104]. A retrospective analysis of 10,853 women enrolled in the EORTC trial showed that, of the 31 local relapses occurring in patients with DCIS, 24 were associated with in situ lesions that overexpressed HER-2/neu. The real meaning of HER-2/ neu overexpression in DCIS is currently the object of the study, given its importance as a prognostic and predictive factor in the invasive cancer. The use of trastuzumab, a monoclonal antibody targeting HER-2/neu, is interesting given the relative frequency of its presence in

between the two arms of the NSABP B-24 trial.

on the invasive ipsilateral recurrence.

182 Cancer Management and Therapy

of its side effects and potential benefits.

**5.3. Other medical therapies**

In agreement with the American Joint Committee on Cancer, microinvasive breast cancer is defined as a DCIS where the invasive component is microscopic and does not exceed the size of 1 mm [105]. In the current literature, microinvasive cancer prevalence accounts for about 10–20% of DCIS cases, and it does not represent more than 1% of all breast cancers [1, 106–110].

The natural history of these lesions is unclear; however, DCIS with microinvasion could be an intermediate stage in the invasive evolution. As a proof of this, the microinvasive carcinoma is often associated with DCIS, particularly large and with comedonecrosis [1, 64], and may be formed by small foci of tumor cells that, after crossing the basal membrane, infiltrate the surrounding stroma [64]. The age of presentation does not seem to be significantly different from that of invasive or in situ forms [106].

Almost all DCIS with microinvasion are identified by the presence of microcalcifications at mammography [111]. Occasionally, the microinvasive carcinoma appears as a palpable mass with serum or blood vessel secretions from the nipple or as Paget's disease [112–114]. Microinvasive lesions tend to be larger in size and therefore more often palpable than purely in situ lesions. The detection of a microinvasion within a DCIS can be extremely difficult for the pathologist because of the many patterns with which the lesion can invade the stroma [77]. Usually, the microinvasion foci tend to be accompanied by a stromal response characterized by inflammatory cells scattered in one neoformed connective matrix [115]. Moreover, the use of immunohistochemical markers specific for the basal membrane or myoepithelial cells can help identify microinvasion in doubtful cases [115].

Concerning the therapeutic implications, data is not uniform. Surgical treatment can be both conservative and radical. According to recent reports, the use of mastectomy is significantly less frequent for this type of lesion than for invasive carcinomas, and the same happens for adjuvant therapies, generally reserved only for patients with triple-negative carcinomas, HER2-positive breast cancer, or with lymph node involvement [106]. The use of adjuvant radiotherapy is even higher in the group of microinvasive carcinoma than in that of invasive one, possibly due to the higher prevalence of conservative surgery.

According to the AIOM guidelines, mastectomy is indicated in these tumors in the presence of large intraductal component, particularly unfavorable histological characteristics (high-grade and comedonecrosis), or when it is not possible to obtain an adequate resection margin with a conservative resection [64]. BCS is also contraindicated after previous chest wall irradiation, during pregnancy, or in the case of multicentric lesions or diffused microcalcifications [110].

Regarding the use of adjuvant systemic treatments, endocrine therapies may be administered in the case of hormone receptor expression, while chemotherapy is not indicated, except in patients with axillary lymph node metastases [64, 106]. There are currently no prospective randomized studies comparing BCS followed by radiotherapy with mastectomy in the subset of patients with microinvasive carcinoma [105].

had a higher local recurrence rate than those with pure DCIS, as well as an intermediate survival rate between in situ and frankly invasive carcinomas. In contrast, Silverstein and Lagios did not detect differences between patients with microinvasive carcinoma and DCIS in terms

Breast and Axilla Treatment in Ductal Carcinoma In Situ http://dx.doi.org/10.5772/intechopen.74340 185

In a review of Adamovich and Simmons, the median time of appearance of a local relapse resulted in 42 months, most of the local recurrences of microinvasive carcinoma were invasive recurrences, and only the 7% were distant ones [110]. A study by Parikh et al. on 393 women with breast cancer treated with BCS and radiotherapy suggested that microinvasion is not predictive of a significant worsening of local recurrence and distant metastasis-free survival, overall survival, and disease-free survival [122]. This study concluded that, despite the greater aggressiveness in treating patients with microinvasion, clinical and pathological characteristics and outcome did not differ for DCIS with and without microinvasion. Even more recent data emerging from Fang et al.'s work confirmed that disease-free survival of over 2 years in patients with microinvasive carcinoma was significantly worse than that of

In conclusion, clinical and pathological features and outcomes do not significantly differ between DCIS with and without microinvasion [106]. Overall survival do not differ significantly in the two groups, which altogether have a good prognosis overall. The prevalence of lymph node metastases in the microinvasive carcinomas is low and does not associate with a prognosis worsening, as it does not lead to an increased risk of recurrence, either local or distant [119]. According with the ASCO guidelines published in 2016, a 6-month clinical follow-

Complete axillary dissection was the only possible approach in surgery until the early 1990s of the last century. Nowadays, the sentinel lymph node biopsy represents the standard in most centers that deal with mammary surgery [64, 82, 124–127] and significantly reduced the complications associated with axillary surgery [128] while providing high levels of accuracy in the staging [129–131]. The multicentric NSABP B-32 trial randomized 5611 women with clinically negative axillary nodes to the sentinel lymph node biopsy alone or followed by axillary dissection [131]. No significant differences in disease-free and overall survival and locoregional recurrences were observed between the two groups at a median follow-up of 96 months.

The concept of sentinel lymph node was born in the 1970s and completely developed 20 years later, based on the principle that tumors are drained from a lymphatic channel through the first sentinel node of that region. In 1991 Giuliano and colleagues first applied the method of sentinel lymph node biopsy at the John Wayne Cancer Institute in the context of breast surgery. They reached 100% accuracy in predicting axillary nodal status in a few

In a recent work, analyzing data from the Surveillance, Epidemiology, and End Results (SEER) registers, Worni and colleagues reported that in 2010 the sentinel lymph node biopsy

years [125, 132, 133], opening the way to the spread of the method.

pure DCIS and similar to that of invasive carcinoma smaller than 5 mm [106].

up together with annual instrumental examinations should be recommended [123].

**7. The role of sentinel lymph node biopsy**

of overall and disease-free survival [121].

Prior to the spread of the sentinel lymph node technique, due to its significant morbidity and poor clinical benefits, axillary dissection was not recommended in the management of noninvasive or microinvasive lesions [109]. With the introduction of the sentinel lymph node biopsy, burdened with much minor complications, axillary surgery has extended also to DCIS in the case of mastectomy, as the technique would not be reliable in the second time if needed [116, 117]. However, in the literature there is insufficient evidence of the efficacy of the sentinel lymph node biopsy for the microinvasive cancer, mainly because the studies are mostly retrospective and based on small sample sizes.

The detection of microinvasive foci at the definitive histological examination of specimen of women initially diagnosed with DCIS is quite frequent. In particular, the upstaging rate to invasive carcinoma varies in the literature about 10–20% of in situ or microinvasive lesions [118]. In the case of unexpected microinvasive carcinoma, the sentinel lymph node biopsy can be performed both in conjunction with the primary lesion excision and later on.

In the literature, the sentinel lymph node metastasis rates reported in the case of microinvasive carcinomas are about 6–10%, and about half of these are micrometastasis [77]. In a recent metaanalysis, Gojon et al. studied the role of the lymph node biopsy in 968 patients with microinvasive carcinoma [116]. It emerged that the macrometastasis rate in the sentinel lymph nodes was 3.2% (CI (95%): 2.1–4.6%) without significant differences between the data of the various considered studies. Patients with macrometastatic sentinel nodes would have a risk of almost 30% of having more non-sentinel lymph node metastases, but, due to the rarity of nodal macrometastases, the global incidence of non-sentinel metastases in microinvasive carcinoma resulted less than 1%. Thereafter, given the low rates of nodal positivity, this meta-analysis does not justify the routine use of sentinel lymph node biopsy in patients with microinvasive carcinoma.

Several studies have tried to identify predictive factors for lymph node involvement but with contrasting results [116]. In addition, many studies have reported excellent prognosis in patients with microinvasive carcinoma, irrespective of the eventual asynchronous lymph node involvement [116]. Some authors reported a similar local or distant recurrence risk in patients with in situ or microinvasive carcinomas and positivity for sentinel lymph biopsy [119]. Then, despite the absence of clear scientific evidence, in the case of microinvasive cancer, the use of the sentinel lymph node biopsy is still recommended, especially given the low morbidity of this practice [77].

The survival of patients with microinvasive carcinoma seems to be a halfway between that of pure DCIS and that of early invasive carcinoma [77]. Some dated studies reported no recurrence after average follow-up of 57 and 47 months, respectively [112, 113]. Kinne et al. reported a disease-free survival of about 94% at a median follow-up of 11.5 years [120]. Solin et al. compared the outcomes of invasive carcinoma with those of DCIS and microinvasive carcinoma treated in the same period [114] and found that patients with microinvasive cancer had a higher local recurrence rate than those with pure DCIS, as well as an intermediate survival rate between in situ and frankly invasive carcinomas. In contrast, Silverstein and Lagios did not detect differences between patients with microinvasive carcinoma and DCIS in terms of overall and disease-free survival [121].

In a review of Adamovich and Simmons, the median time of appearance of a local relapse resulted in 42 months, most of the local recurrences of microinvasive carcinoma were invasive recurrences, and only the 7% were distant ones [110]. A study by Parikh et al. on 393 women with breast cancer treated with BCS and radiotherapy suggested that microinvasion is not predictive of a significant worsening of local recurrence and distant metastasis-free survival, overall survival, and disease-free survival [122]. This study concluded that, despite the greater aggressiveness in treating patients with microinvasion, clinical and pathological characteristics and outcome did not differ for DCIS with and without microinvasion. Even more recent data emerging from Fang et al.'s work confirmed that disease-free survival of over 2 years in patients with microinvasive carcinoma was significantly worse than that of pure DCIS and similar to that of invasive carcinoma smaller than 5 mm [106].

In conclusion, clinical and pathological features and outcomes do not significantly differ between DCIS with and without microinvasion [106]. Overall survival do not differ significantly in the two groups, which altogether have a good prognosis overall. The prevalence of lymph node metastases in the microinvasive carcinomas is low and does not associate with a prognosis worsening, as it does not lead to an increased risk of recurrence, either local or distant [119]. According with the ASCO guidelines published in 2016, a 6-month clinical followup together with annual instrumental examinations should be recommended [123].

## **7. The role of sentinel lymph node biopsy**

Regarding the use of adjuvant systemic treatments, endocrine therapies may be administered in the case of hormone receptor expression, while chemotherapy is not indicated, except in patients with axillary lymph node metastases [64, 106]. There are currently no prospective randomized studies comparing BCS followed by radiotherapy with mastectomy in the subset

Prior to the spread of the sentinel lymph node technique, due to its significant morbidity and poor clinical benefits, axillary dissection was not recommended in the management of noninvasive or microinvasive lesions [109]. With the introduction of the sentinel lymph node biopsy, burdened with much minor complications, axillary surgery has extended also to DCIS in the case of mastectomy, as the technique would not be reliable in the second time if needed [116, 117]. However, in the literature there is insufficient evidence of the efficacy of the sentinel lymph node biopsy for the microinvasive cancer, mainly because the studies are mostly

The detection of microinvasive foci at the definitive histological examination of specimen of women initially diagnosed with DCIS is quite frequent. In particular, the upstaging rate to invasive carcinoma varies in the literature about 10–20% of in situ or microinvasive lesions [118]. In the case of unexpected microinvasive carcinoma, the sentinel lymph node biopsy can